<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002829.pub4" GROUP_ID="NEUROMUSC" ID="814300060115352231" MERGED_FROM="" MODIFIED="2011-05-11 10:51:29 +0200" MODIFIED_BY="Ruth Brassington" REVIEW_NO="022" REVMAN_SUB_VERSION="5.1.1" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2011-05-11 10:51:29 +0200" MODIFIED_BY="Ruth Brassington">
<TITLE MODIFIED="2008-07-15 17:17:46 +0100" MODIFIED_BY="Kate Jewitt">Antioxidant treatment for amyotrophic lateral sclerosis or motor neuron disease</TITLE>
<CONTACT MODIFIED="2011-05-11 10:51:29 +0200" MODIFIED_BY="Ruth Brassington"><PERSON ID="7968" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Richard</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Orrell</LAST_NAME><SUFFIX>BSc MD FRCP</SUFFIX><POSITION>Senior Lecturer and Consultant Neurologist</POSITION><EMAIL_1>r.orrell@ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Clinical Neurosciences</DEPARTMENT><ORGANISATION>University College London Institute of Neurology</ORGANISATION><ADDRESS_1>Royal Free Campus</ADDRESS_1><ADDRESS_2>Rowland Hill Street</ADDRESS_2><CITY>London</CITY><ZIP>NW2 3PF</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>44 20 7830 2387</PHONE_1><FAX_1>44 20 7472 6829</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-05-11 10:51:29 +0200" MODIFIED_BY="Ruth Brassington"><PERSON ID="7968" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Richard</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Orrell</LAST_NAME><SUFFIX>BSc MD FRCP</SUFFIX><POSITION>Senior Lecturer and Consultant Neurologist</POSITION><EMAIL_1>r.orrell@ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Clinical Neurosciences</DEPARTMENT><ORGANISATION>University College London Institute of Neurology</ORGANISATION><ADDRESS_1>Royal Free Campus</ADDRESS_1><ADDRESS_2>Rowland Hill Street</ADDRESS_2><CITY>London</CITY><ZIP>NW2 3PF</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>44 20 7830 2387</PHONE_1><FAX_1>44 20 7472 6829</FAX_1></ADDRESS></PERSON><PERSON ID="7769" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Russell</FIRST_NAME><MIDDLE_INITIALS>JM</MIDDLE_INITIALS><LAST_NAME>Lane</LAST_NAME><POSITION>Consultant Neurologist</POSITION><EMAIL_1>r.lane@imperial.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>West London Neurosciences Centre</DEPARTMENT><ORGANISATION>Imperial College NHS Trust</ORGANISATION><ADDRESS_1>Charing Cross Hospital, Fulham Palace Road</ADDRESS_1><CITY>London</CITY><ZIP>W6 8RF</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 020 8846 1194</PHONE_1><FAX_1>+ 44 020 8846 7487</FAX_1></ADDRESS></PERSON><PERSON ID="15432" ROLE="AUTHOR"><FIRST_NAME>Mark</FIRST_NAME><LAST_NAME>Ross</LAST_NAME><SUFFIX>MD</SUFFIX><EMAIL_1>ross.mark@mayo.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Mayo Clinic Scottsdale</ORGANISATION><ADDRESS_1>13400 East Shea Boulevard</ADDRESS_1><CITY>Scottsdale</CITY><REGION>Arizona</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 480 301 7628</PHONE_1><FAX_1>+1 480 301 8451</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-12-14 14:14:21 +0000" MODIFIED_BY="Kate Jewitt">
<UP_TO_DATE>
<DATE DAY="22" MONTH="6" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="22" MONTH="6" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="22" MONTH="6" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2011-05-10 19:35:55 +0100" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-05-10 19:35:55 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="13" MONTH="2" YEAR="2011"/>
<DESCRIPTION>
<P>We have included reference to a phase II clinical study of coenzyme Q10 in ALS. Edavarone has been included in the background. Searches were updated to 22 June 2010. The Cochrane Collaboration 'Risk of bias' tool was incorporated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-12-14 14:15:02 +0000" MODIFIED_BY="Kate Jewitt">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="1" MONTH="9" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-03-28 10:47:40 +0100" MODIFIED_BY="Kate Jewitt">
<INTERNAL_SOURCES MODIFIED="2011-03-28 10:47:33 +0100" MODIFIED_BY="Kate Jewitt">
<SOURCE MODIFIED="2011-03-28 10:47:33 +0100" MODIFIED_BY="Kate Jewitt">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2011-03-28 10:47:40 +0100" MODIFIED_BY="Kate Jewitt">
<SOURCE MODIFIED="2011-03-28 10:47:40 +0100" MODIFIED_BY="Kate Jewitt">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-05-10 22:23:43 +0100" MODIFIED_BY="Ruth Brassington">
<SUMMARY MODIFIED="2011-05-10 19:43:25 +0100" MODIFIED_BY="Ruth Brassington">
<TITLE MODIFIED="2008-06-18 15:49:48 +0100" MODIFIED_BY="Kate Jewitt">Antioxidants for treating amyotrophic lateral sclerosis</TITLE>
<SUMMARY_BODY MODIFIED="2011-05-10 19:43:25 +0100" MODIFIED_BY="Ruth Brassington">
<P>There is no cure for amyotrophic lateral sclerosis, also known as motor neuron disease, which is a progressively disabling and ultimately fatal disease. Antioxidants, including vitamins C, E, selegiline, selenium, methionineacetylcysteine, and coenzyme Q10, have been suggested as possible treatments and some of these are commonly advised by physicians treating people with amyotrophic lateral sclerosis. In this updated review, we identified 10 studies involving a total of 1015 participants. We did not find any well-designed randomized controlled trial evidence to support the use of these medications. Trials of antioxidants identified in this review were generally of poor methodological quality and lacked statistical power. However, antioxidants are generally well tolerated without serious adverse effects.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-05-10 22:03:04 +0100" MODIFIED_BY="Ruth Brassington">
<ABS_BACKGROUND MODIFIED="2011-03-28 10:47:23 +0100" MODIFIED_BY="Kate Jewitt">
<P>Free radical accumulation and oxidative stress have been proposed as contributing to the progression of amyotrophic lateral sclerosis (or motor neuron disease). A range of antioxidant medications have been studied. This is an updated review. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To examine the effects of antioxidant medication in the treatment of people with amyotrophic lateral sclerosis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-05-10 19:38:57 +0100" MODIFIED_BY="Ruth Brassington">
<P>We searched the Cochrane Neuromuscular Disease Group Specialized Register (11 May 2010), the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2010, Issue 2), MEDLINE (January 1966 to April 2010), EMBASE (January 1980 to May 2010).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomized or quasi-randomized controlled trials of antioxidant treatment for amyotrophic lateral sclerosis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-05-10 19:36:41 +0100" MODIFIED_BY="Ruth Brassington">
<P>The authors independently applied the selection criteria and assessed study quality; two authors performed independent data extraction.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-05-10 22:03:01 +0100" MODIFIED_BY="Ruth Brassington">
<P>The search identified 25 studies for consideration but only 10 studies met the inclusion criteria. These included a total of 1015 participants. Generally the studies were poorly designed and underpowered, with low numbers of participants and short durations. Only two studies used our predetermined primary outcome measure (survival at 12 months treatment). However, sufficient data were available from four studies to allow meta-analysis.<BR/>In the individual studies, no significant effect was observed for vitamin E 500 mg twice daily; vitamin E 1 g five times daily; acetylcysteine 50 mg/kg daily by subcutaneous infusion; a combination of L-methionine 2 g, vitamin E 400 international units, and selenium (Alsemet) 0.03 mg three times daily; or coenzyme Q10 1800 mg/day and 2700 mg/day. No significant effect was observed on the primary outcome measure in a meta-analysis of all antioxidants combined. No significant differences were demonstrated in any of the secondary outcome measures. The antioxidants were generally well tolerated, without serious side effects.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-05-10 22:03:04 +0100" MODIFIED_BY="Ruth Brassington">
<P>There is insufficient evidence of efficacy of individual antioxidants, or antioxidants in general, in the treatment of people with amyotrophic lateral sclerosis. One study reported a mild positive effect but this was not supported in our analysis. If future trials of antioxidant medications are performed, careful attention should be given to sample size, outcome measures, and duration of the trials. The high tolerance and safety, and relatively low cost of vitamins C and E, explain the continuing use of these vitamins by physicians and people with amyotrophic lateral sclerosis. While there is no substantial clinical trial evidence to support their clinical use, there is no clear contraindication.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-05-10 22:23:43 +0100" MODIFIED_BY="Ruth Brassington">
<BACKGROUND MODIFIED="2011-05-10 22:03:13 +0100" MODIFIED_BY="Ruth Brassington">
<P>Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a progressive neurodegenerative disease that causes loss of power and function of skeletal muscles generally with difficulty walking, using the arms, speaking and swallowing. The course of the disease is variable but is usually relatively rapid, with an average length of time from the first symptoms and signs of the disease to death of around 3.5 years. Death is most frequently due to respiratory failure. For a review see <LINK REF="REF-Eisen-1998" TYPE="REFERENCE">Eisen 1998</LINK>.</P>
<P>ALS occurs in individuals of all ethnic origins, worldwide. Males are affected slightly more frequently than females. Adults of all ages may be affected, with peak incidence between 50 and 70 years of age. The worldwide prevalence is 0.75 to 9 per 100,000 population, with an annual incidence of 0.3 to 2 per 100,000 population (<LINK REF="REF-Eisen-1998" TYPE="REFERENCE">Eisen 1998</LINK>; <LINK REF="REF-Logroscino-2005" TYPE="REFERENCE">Logroscino 2005</LINK>; <LINK REF="REF-Sejvar-2005" TYPE="REFERENCE">Sejvar 2005</LINK>). The cause of ALS remains unknown, but about 5% to 10% of patients have a family history of other affected members and dominant and recessive forms of inheritance of ALS are now recognised. Mutations of the copper/zinc superoxide dismutase (SOD1) gene have been found in both familial and rarely in apparently sporadic forms (<LINK REF="REF-Rosen-1993" TYPE="REFERENCE">Rosen 1993</LINK>). These amount to around 2% of all patients with ALS.</P>
<P>Until recently, treatment options have only been symptomatic and supportive. Recent studies have suggested a mild beneficial effect of riluzole in slowing progression of the disease and increasing survival (<LINK REF="REF-Lacomblez-1996" TYPE="REFERENCE">Lacomblez 1996</LINK>) and are the subject of a separate Cochrane review (<LINK REF="REF-Miller-2007" TYPE="REFERENCE">Miller 2007</LINK>). Many other agents have been tried in ALS but generally without clear benefit.</P>
<P>One of the proposed mechanisms of neuronal death in ALS is free radical accumulation resulting from oxidative stress (<LINK REF="REF-Bergeron-1996" TYPE="REFERENCE">Bergeron 1996</LINK>). Free radicals are produced in normal and abnormal biological cellular metabolic processes that involve molecular oxygen. 'Oxidative stress' refers to an increase in the generation of oxygen derived species (superoxide anion, hydroxyl radical, hydrogen peroxide) beyond the ability of normal antioxidative defences to 'neutralize' them. An excess of these free radicals may lead to oxidative damage to lipids, proteins and nucleic acids, causing cell death. Free radicals are normally 'neutralized' by antioxidant enzymes (superoxide dismutase, catalase and glutathione peroxidase) and nutrient derived antioxidants such as vitamins C and E, carotenes, flavonoids, glutathione, uric acid and taurine (<LINK REF="REF-Sardesi-1995" TYPE="REFERENCE">Sardesi 1995</LINK>). Nitric oxide may interact with superoxide anion to form highly reactive peroxynitrites (<LINK REF="REF-Beckman-1993" TYPE="REFERENCE">Beckman 1993</LINK>). Increased iron, selenium and glutathione peroxidase activity (<LINK REF="REF-Ince-1994" TYPE="REFERENCE">Ince 1994</LINK>) and other heavy metals and trace elements including manganese (<LINK REF="REF-Mitchell-1987" TYPE="REFERENCE">Mitchell 1987</LINK>) have been identified in the spinal cord of ALS patients. Increased oxidative stress may have a primary role in causing ALS. This increase might result from altered mitochondrial energy metabolism related to age, environmental factors that lead to increased free radical production, or glutamate mediated excitotoxicity.</P>
<P>Many natural biological agents have antioxidant effects. Some of these are readily available, such as vitamins C and E, and are commonly advised by physicians for patients with ALS. Patients may take individual antioxidant agents or proprietary combinations. Whilst the cost of individual agents may be low, more complex proprietary combinations can have a significant cost. It is important to determine the evidence for benefit, and possible harm, from these agents.</P>
<P>More commonly considered antioxidant medications in ALS include the following.</P>
<SUBSECTION>
<HEADING LEVEL="2">Vitamin C (ascorbic acid)</HEADING>
<P>Vitamin C is a naturally occurring antioxidant. It is usually taken orally.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Vitamin E (&#945;-tocopherol)</HEADING>
<P>Vitamin E is a naturally occurring antioxidant. It is taken orally but very little vitamin E appears to cross the blood brain barrier after oral administration (<LINK REF="REF-Halliwell-2001" TYPE="REFERENCE">Halliwell 2001</LINK>). Studies of vitamin E in the SOD1 (copper/zinc superoxide dismutase gene) mutant transgenic mouse model of ALS have suggested efficacy in delaying disease onset (<LINK REF="REF-Gurney-1996" TYPE="REFERENCE">Gurney 1996</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">L-deprenyl (selegiline)</HEADING>
<P>Selegiline is a selective monoamine oxidase B inhibitor. Selegiline has been reported to increase SOD activity in the basal ganglia of rats, and possibly has additional antioxidant properties (<LINK REF="REF-Knoll-1989" TYPE="REFERENCE">Knoll 1989</LINK>). It has been used in Parkinson's disease for presumed neuroprotective and antioxidant properties. Its clinical efficacy in that condition has been questioned and is currently under review. Some trials in patients with ALS have already been undertaken (<LINK REF="STD-Janik-1996" TYPE="STUDY">Janik 1996</LINK>; <LINK REF="STD-Jossan-1994" TYPE="STUDY">Jossan 1994</LINK>; <LINK REF="STD-Lange-1998" TYPE="STUDY">Lange 1998</LINK>; <LINK REF="STD-Mazzini-1994" TYPE="STUDY">Mazzini 1994</LINK>; <LINK REF="STD-Mitchell-1995" TYPE="STUDY">Mitchell 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">N-acetylcysteine</HEADING>
<P>N-acetylcysteine is a precursor of glutathione, a natural intracellular antioxidant. One trial has already been undertaken (<LINK REF="STD-Louwerse-1995" TYPE="STUDY">Louwerse 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Dehydroepiandrosterone</HEADING>
<P>Dehydroepiandrosterone is a steroid synthesized in brain glial cells. This agent has been investigated in patients with ALS and is proposed to have antioxidant properties (<LINK REF="REF-Eisen-1998" TYPE="REFERENCE">Eisen 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Combination antioxidant therapy</HEADING>
<P>Experience has been reported with an 'array' of antioxidants in patients with ALS; using N-acetylcysteine, vitamin C, vitamin E, N-acetylmethionine and dithiothreitol or its isomer dithioerythritol (<LINK REF="STD-Vyth-1996" TYPE="STUDY">Vyth 1996</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">AEOL-10150</HEADING>
<P>AEOL-10150 is a small molecule antioxidant analogous to the catalytic site of superoxide dismutase. This has been investigated for ALS in a phase I clinical trial (<LINK REF="REF-Orrell-2006" TYPE="REFERENCE">Orrell 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Edavarone</HEADING>
<P>Edavarone (3-methyl-1-phenyl-pyrazolin-5-one) is a newly developed free radical scavenging agent, which has been investigated in a range of conditions including stroke (<LINK REF="REF-Yoshida-2006" TYPE="REFERENCE">Yoshida 2006</LINK>). This has been studied in ALS (<LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Coenzyme Q10</HEADING>
<P>Coenzyme Q10 (CoQ10, or ubiquinone) is an oil-soluble, vitamin-like substance present primarily in mitochondria. It is a component of the electron transport chain and a free radical scavenger. Coenyme Q10 has been suggested as a potential treatment for a wide range of conditions, because of its antioxidant effect. A phase II trial in ALS was reported (<LINK REF="STD-QALS-Study-Group-2009" TYPE="STUDY">QALS Study Group 2009</LINK>).</P>
<P>This is an update to the original review.</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-05-10 19:48:36 +0100" MODIFIED_BY="Ruth Brassington">
<P>We set out to examine the efficacy of antioxidant medication in the treatment of ALS. We undertook a broad approach by studying all agents with a generally accepted antioxidant mechanism, singly or in combination; and a narrower approach by studying the effects of the individual agents.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-05-10 22:23:32 +0100" MODIFIED_BY="Ruth Brassington">
<SELECTION_CRITERIA MODIFIED="2011-05-10 22:23:28 +0100" MODIFIED_BY="Ruth Brassington">
<CRIT_STUDIES MODIFIED="2011-05-10 19:48:42 +0100" MODIFIED_BY="Ruth Brassington">
<P>We included all randomized or quasi-randomized (for example alternate allocation) controlled trials of antioxidant treatment for ALS.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-05-10 22:03:42 +0100" MODIFIED_BY="Ruth Brassington">
<P>We included clinical trials of patients with ALS at all stages and in all subtypes. This included all sites of onset, other clinical features, and included familial and nonfamilial disease patients. Amyotrophic lateral sclerosis was defined in terms generally agreed as compatible with the clinical diagnosis, including features of upper and lower motor neuron involvement, absence of sensory signs not otherwise explicable, and a progressive course. Diagnostic criteria formulated by the World Federation of Neurology Sub-Committee on Neuromuscular Diseases, at El Escorial (<LINK REF="REF-Brooks-1994" TYPE="REFERENCE">Brooks 1994</LINK>) have been proposed for use in clinical trials, and were used where available. However, these criteria post date some of the trials considered and they have been further refined since their first publication.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-05-10 22:03:47 +0100" MODIFIED_BY="Ruth Brassington">
<P>We included any form of treatment considered to have an antioxidant effect. This includes vitamin C, vitamin E, selegiline, N-acetylcysteine, dehydroepiandrosterone, N-acetylmethionine, dithiothreitol and coenzyme Q10.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-05-10 22:23:28 +0100" MODIFIED_BY="Ruth Brassington">
<P>A summary of findings table (SOF) will be added to the next update. Outcomes to address include survival, muscle strength, respiratory function, quality of life and adverse events.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-05-10 22:23:28 +0100" MODIFIED_BY="Ruth Brassington">
<P>Antioxidants were analyzed initially as a group, with additional subgroup analysis of individual antioxidants. The primary outcome measure was survival (free of tracheostomy or ventilatory support) after 12 months treatment.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-05-10 22:03:53 +0100" MODIFIED_BY="Ruth Brassington">
<P>Secondary measures included:</P>
<OL>
<LI>survival as a function of time (3, 6, 9, 15 and 18 months);</LI>
<LI>duration of disease as measured by time from randomization to death or mechanical ventilation with a tracheostomy;</LI>
<LI>quantitative muscle testing;</LI>
<LI>functional rating scales;</LI>
<LI>subjective rating scales;</LI>
<LI>quality of life assessments of patients and caregivers;</LI>
<LI>adverse effects - severe (leading to cessation of medication), and mild (medication continued).</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-05-10 22:03:58 +0100" MODIFIED_BY="Ruth Brassington">
<ELECTRONIC_SEARCHES MODIFIED="2011-05-10 22:03:58 +0100" MODIFIED_BY="Ruth Brassington">
<P>We searched the Cochrane Neuromuscular Disease Group Specialized Register (11 May 2010) using 'amyotrophic lateral sclerosis' and its synonyms 'motor neuron disease' and 'motor neuron disease' for trials of the following agents, using the search terms 'vitamin C', 'ascorbic acid', 'vitamin E', 'alpha-tocopherol', 'selegiline', 'deprenyl', 'n-acetyl cysteine', 'n-acetyl-l-cysteine', 'n-acetylcysteine', 'acetylcysteine', 'superoxide dismutase', 'SOD', 'dehydroepiandrosterone', the generic term 'antioxidant','AEOL-10150', 'coenzyme Q10', 'coQ10', and 'ubiquinone'. We adapted this strategy to search the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 2, 2010 in <I>The Cochrane Library</I>), MEDLINE (January 1966 to April 2010) and EMBASE (January 1980 to May 2010).</P>
<P>For the MEDLINE, EMBASE and CENTRAL search strategies, see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-04-04 12:59:55 +0100" MODIFIED_BY="Kate Jewitt">
<P>We checked the bibliographies in reports of the randomized trials and contacted their authors and other experts in the field to identify additional published or unpublished data. Manufacturers of antioxidant medication were contacted for details of any randomized trials performed.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-05-10 22:23:32 +0100" MODIFIED_BY="Ruth Brassington">
<P>Three authors checked the titles and abstracts identified. We obtained the full text of all potentially relevant studies for independent assessment by all authors. The authors decided which trials fitted the inclusion criteria and assessed risk of bias. We resolved disagreements about inclusion criteria by discussion.</P>
<P>We assessed risk of bias using The Cochrane Collaboration 'Risk of bias' tool. The domains were: adequate sequence generation, allocation concealment, blinding (all outcomes), incomplete outcome data addressed, free of selective reporting, and free of other bias. These were scored as yes, no, or unclear, using Cochrane defined criteria (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).</P>
<P>Two authors performed data extraction independently, and all authors checked data extraction. We obtained missing data from the trial authors whenever possible. We tested for heterogeneity in the results where possible. Sensitivity analysis was performed if there was significant heterogeneity in the outcomes. Antioxidants as a group were assessed, with additional subgroup analysis of individual antioxidant agents.</P>
<P>We calculated relative risks for binary outcomes (such as survival) and a difference in weighted means for continuous outcomes (for example muscle strength) to determine treatment effect across trials (using a fixed-effect model) with the Cochrane statistical package Review Manager (RevMan), where possible. Results were to be expressed as relative risks with 95% confidence intervals and risk differences with 95% confidence intervals for dichotomous outcomes and weighted mean difference and 95% confidence intervals for continuous outcomes. We analyzed all the primary and secondary outcomes under consideration whenever the data allowed.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-05-10 22:23:43 +0100" MODIFIED_BY="Ruth Brassington">
<STUDY_DESCRIPTION MODIFIED="2011-05-10 22:23:36 +0100" MODIFIED_BY="Ruth Brassington">
<P>A search of the Cochrane Neuromuscular Disease Group (NMD) Specialized Register, MEDLINE, EMBASE and other sources as described revealed 25 possible randomized controlled trials. The number of references returned from the databases was: MEDLINE 212, EMBASE 27, CENTRAL 23, NMD register 4. Two studies in Polish were translated into English (Kwiecinski 2001; <LINK REF="STD-Szczudlik-1998" TYPE="STUDY">Szczudlik 1998</LINK>), as was one study in Chinese (<LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Excluded studies (see 'Characteristics of excluded studies')</HEADING>
<P>One study (<LINK REF="STD-Vyth-1996" TYPE="STUDY">Vyth 1996</LINK>) was excluded as it used historical controls and was not randomized.</P>
<P>We excluded four study reports (Engel 1969; <LINK REF="STD-Janik-1996" TYPE="STUDY">Janik 1996</LINK>; Mitchell 1993; Stevic 1998) as they were abstracts of subsequently published studies (<LINK REF="STD-Dorman-1969" TYPE="STUDY">Dorman 1969</LINK>; Kwiecinski 2001; <LINK REF="STD-Mitchell-1995" TYPE="STUDY">Mitchell 1995</LINK>; <LINK REF="STD-Stevic-2001" TYPE="STUDY">Stevic 2001</LINK>). Mitchell 1994 described the same study as <LINK REF="STD-Mitchell-1995" TYPE="STUDY">Mitchell 1995</LINK>, and Professor Mitchell also provided further unpublished details of this study.</P>
<P>We excluded eight studies (<LINK REF="STD-Chio-1998" TYPE="STUDY">Chio 1998</LINK>; <LINK REF="STD-Dorman-1969" TYPE="STUDY">Dorman 1969</LINK>; Kwiecinski 2001; <LINK REF="STD-Mazzini-1994" TYPE="STUDY">Mazzini 1994</LINK>; <LINK REF="STD-Quick-1969" TYPE="STUDY">Quick 1969</LINK>; <LINK REF="STD-Szczudlik-1998" TYPE="STUDY">Szczudlik 1998</LINK>; <LINK REF="STD-Wechsler-1940" TYPE="STUDY">Wechsler 1940</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>) as there was inadequate concealment of allocation of treatment. <LINK REF="STD-Chio-1998" TYPE="STUDY">Chio 1998</LINK> was an open unblinded cross-over, sequentially randomized study. <LINK REF="STD-Dorman-1969" TYPE="STUDY">Dorman 1969</LINK> was an unblinded nonrandomized study without controls. <LINK REF="STD-Quick-1969" TYPE="STUDY">Quick 1969</LINK> was an open nonrandomized study. Kwiecinski 2001 was an open randomized study. <LINK REF="STD-Mazzini-1994" TYPE="STUDY">Mazzini 1994</LINK> randomized the patients sequentially and was open and unblinded. <LINK REF="STD-Szczudlik-1998" TYPE="STUDY">Szczudlik 1998</LINK> was an open study. <LINK REF="STD-Wechsler-1940" TYPE="STUDY">Wechsler 1940</LINK> was an observational nonrandomized, uncontrolled unblinded study. <LINK REF="STD-Ascherio-2005" TYPE="STUDY">Ascherio 2005</LINK> was a prospective study of prevention of occurrence of disease. <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK> was an open randomized study, not double blinded.</P>
<P>There remained ten trials that fulfilled our selection criteria for randomized controlled trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Included studies (see 'Characteristics of included studies')</HEADING>
<P>A total of 1015 patients were studied in these 10 trials. Two of the studies were cross-over studies (<LINK REF="STD-Jossan-1994" TYPE="STUDY">Jossan 1994</LINK>; <LINK REF="STD-Mitchell-1995" TYPE="STUDY">Mitchell 1995</LINK>), comprising 66 patients. The remaining seven noncross-over studies included a total of 383 treated patients and 367 placebo patients. One hundred and ten patients and 75 controls were involved in an adaptive, two stage, phase II design study (<LINK REF="STD-QALS-Study-Group-2009" TYPE="STUDY">QALS Study Group 2009</LINK>). An additional 14 patients were treated with amino acids or nimodipine (<LINK REF="STD-Apostolski-1998" TYPE="STUDY">Apostolski 1998</LINK>). The potential antioxidants vitamin C, vitamin E (a-tocopherol), coenzyme Q, selenium, beta-carotene, N-acetylcysteine, selegiline and coenzyme Q10 were studied. Methionine was also included in combination as it may "enhance methylation of normal or abnormally hypomethylated DNA in motor neurons or possibly in other cells that influence motor neurons by deficiency or toxic mechanism" (<LINK REF="STD-Stevic-2001" TYPE="STUDY">Stevic 2001</LINK>).</P>
<P>
<LINK REF="STD-Apostolski-1998" TYPE="STUDY">Apostolski 1998</LINK>
<BR/>This was described as a double-blind study of Alsamin, which is a combination of vitamin E (135 international units (IU)), selenium (3 x 10<SUP>-5 </SUP>g) organically bound in baker's yeast, &#946;-carotene (4500 IU), amino acids: L-arginine (0.15 g), L-methionine (2.0 g), L-leucine (4.0 g), L-isoleucine (3.0 g), and L-valine (2.0 g), and the calcium channel blocker nimodipine (20 mg), taken three times daily. The study was conducted at a single site in Yugoslavia. Thirty-five participants were studied, 60% were male and the mean age was 54 years. Patients were divided into five groups of seven. Groups took either placebo; Alsamin; a combination of selenium, vitamin E and &#946;-carotene; a combination of amino acids; or nimodipine 20 mg three times daily.</P>
<P>Diagnosis of ALS was by the World Federation of Neurology criteria.</P>
<P>The primary endpoint was evaluation of several antioxidative enzymes: copper zinc superoxide dismutase, glutathione peroxidase, catalase, glutathione reductase in erythrocytes and plasma glutathione transferase.</P>
<P>The secondary endpoint was a clinical assessment using the Norris score, made at the beginning and after nine weeks of treatment.</P>
<P>The study duration was 63 days.</P>
<P>
<LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK>
<BR/>This was a randomized, placebo controlled double-blind study, of alpha-tocopherol (vitamin E) 500 mg twice daily. The preparation Toco 500 was used. In addition all patients were taking riluzole, which has demonstrated a mild effect in prolonging survival in ALS. The study was conducted at 28 sites in France. Two hundred and eighty-eight participants were studied, 55% were male and the mean age was 64 years.</P>
<P>Diagnosis of ALS was probable or definite ALS by the El Escorial criteria. To be included, all patients had to be treated with riluzole for at least three months without side effects. Exclusion criteria included dementia or other major psychiatric disorders, other serious disease or handicap, forced vital capacity less than 60%, monoclonal gammopathy, conduction blocks, abnormal liver function tests, taking vitamin E or hepatotoxic drugs.</P>
<P>The primary endpoint was the change in functional status of each patient using the modified Norris limb scale.</P>
<P>Secondary endpoints included survival, bulbar function assessed with the Norris bulbar scale, and manual muscle testing. Fatigue, limb stiffness, cramps and fasciculations were assessed using visual analogue scales. Respiratory function, quality of life using the Sickness Impact Profile (SIP) and the ALS Health State scale were measured. Biological markers of oxidative stress (plasma thiobarbituric acid, erythrocyte superoxide dismutase, and erythrocyte glutathione peroxidase) were studied in a subgroup of 122 patients.</P>
<P>The study duration was 12 months.</P>
<P>
<LINK REF="STD-Ellis-1997" TYPE="STUDY">Ellis 1997</LINK>
<BR/>A randomized, placebo controlled, double-blind study, of a cocktail of six antioxidants (coenzyme Q (240 mg), vitamin E (1600 IU), vitamin C (2000 mg), selenium (100 mg), beta-carotene (10 mg) and N-acetylcysteine (200 mg)).</P>
<P>The study was performed at a single centre in the USA. Ten patients were included. The study was presented in abstract form only, and age of participants, inclusion and exclusion criteria were not given. The trial included an initial six month observation period followed by randomization and six months treatment.</P>
<P>The primary endpoint was rate of change in the Appel Rating Scale score.</P>
<P>The secondary endpoints included safety and blood markers of oxidative damage.</P>
<P>
<LINK REF="STD-Graf-2005" TYPE="STUDY">Graf 2005</LINK>
<BR/>This was described as a double-blind study of vitamin E; alpha-tocopherol (Schwarzhaupt, Cologne, Germany) 1 g was given five times spread though the day. The study was performed at six sites in Germany. One hundred and sixty participants, 65% male, were studied. The mean age in the vitamin E group was 59 years and in the placebo group it was 57 years. Ninety-eight per cent of patients were taking riluzole. Twenty-three per cent were taking vitamin E before the onset of the study.<BR/>Diagnosis was probable or definite ALS using the El Escorial criteria. Inclusion criteria were: less than five years disease duration, and treatment with riluzole. Exclusion criteria were not stated.<BR/>The primary endpoint was survival, as measured by time to death, tracheostomy or permanent assisted ventilation during the period of the study.<BR/>Secondary endpoints were rate of deterioration of function assessed by the modified Norris limb and bulbar scales, manual muscle testing (BMRC), spasticity scale, ventilatory function, and the Sickness Impact Profile (SIP ALS/19). Vitamin E levels were measured for a compliance check.</P>
<P>
<LINK REF="STD-Jossan-1994" TYPE="STUDY">Jossan 1994</LINK>
<BR/>A randomized, cross-over, double-blind study of selegiline 10 mg daily.</P>
<P>The study was performed at a single centre in Sweden. Ten patients were included, with a mean age of 50 years. Patients had World Federation of Neurology (<LINK REF="REF-Brooks-1994" TYPE="REFERENCE">Brooks 1994</LINK>) diagnosis of ALS. Inclusion and exclusion criteria were not stated.</P>
<P>The patients took the drug for 12 weeks, followed by 12 weeks washout and 12 weeks placebo.</P>
<P>The primary endpoint was not stated. Other endpoints were Norris score, bulbar and spinal scores. Monoamine oxidase B was estimated in platelets.</P>
<P>
<LINK REF="STD-Lange-1998" TYPE="STUDY">Lange 1998</LINK>
<BR/>A randomized, placebo controlled, double-blind study of selegiline 5 mg twice daily.</P>
<P>The study was performed at two sites in the USA. Criteria for classical ALS were used, although El Escorial or World Federation of Neurology criteria were not stated. One hundred and thirty-three patients were included, with a mean age of 57 years.</P>
<P>Inclusion criteria were: patients aged 25 to 65 years, symptom duration less than three years, mild to moderate disease with Appel ALS total score 30 to 80, and no drug therapy for at least three months before enrolment.</P>
<P>Exclusion criteria were: multifocal motor neuropathy with conduction block, paraproteinemia, elevated GM1 antibodies, sensorimotor peripheral neuropathy, previous infection with poliovirus, lower motor neuron disease only, primary lateral sclerosis, previous allergy to selegiline, abnormal endocrinology, serious medical problems, and poor family support.</P>
<P>Primary endpoint was rate of change of Appel ALS (AALS) total score.</P>
<P>Secondary endpoints were AALS component scores and survival analysis.</P>
<P>The study duration was six months. Participants with a AALS score below 115 or forced vital capacity below 39% predicted were considered treatment failures and entered an open-label phase.</P>
<P>
<LINK REF="STD-Louwerse-1995" TYPE="STUDY">Louwerse 1995</LINK>
<BR/>A randomized, placebo controlled, double-blind study, of acetylcysteine 50 mg/kg subcutaneous infusion daily. A similar placebo was used.</P>
<P>The study was performed at a single centre in the Netherlands. One hundred and ten patients were included, with a mean age 58 years. Diagnosis was of probable or definite ALS by the El Escorial criteria.</P>
<P>Inclusion criteria were not stated. Exclusion criteria were: aged younger than 20 years or older than 80 years; first or second degree family member with ALS; signs of dementia or parkinsonism; serious mental illness; life expectancy less than six months due to another disease; previously used drugs such as antioxidants, mucolytic drugs, glutamate antagonists and chelating agents.</P>
<P>Primary endpoint was survival, defined by death from all causes, long-term assisted ventilation, tracheostomy, and positive-pressure breathing.</P>
<P>Secondary endpoints were rates of disease progression as expressed by manual muscle strength testing, myometry, forced vital capacity, ability to perform activities of daily living, degree of independence and bulbar function.</P>
<P>The study duration was 12 months.</P>
<P>
<LINK REF="STD-Mitchell-1995" TYPE="STUDY">Mitchell 1995</LINK>
<BR/>A cross-over, placebo controlled, double-blind study of selegiline 10 mg daily.</P>
<P>The study was conducted at a single centre in England. Fifty-six patients were included. The age was not stated. This study was published as a letter; with additional details in Mitchell 1993, Mitchell 1994, and unpublished data as provided by Professor Mitchell. Diagnosis was of motor neuron disease (MND), which is an alternative term for ALS, made by two consultant neurologists. No more formal criteria were used. It was stated that at the time of the trial these had not been formulated.</P>
<P>The primary outcome was not stated. Other measures included hand held myometry, hand grip strength, Barthel Disability Index, Rankin Disability Scale, Bulbar Rating Scale, quality of life scale. Whole blood and serum glutathione peroxidase, erythrocyte superoxide dismutase (SOD), serum caeruloplasmin, leucocyte and plasma ascorbic acid, and serum tocopherol were measured.</P>
<P>The study had a cross-over design, both groups taking placebo for four weeks, 16 weeks on medication or placebo, four weeks placebo, 16 weeks on the alternative medication or placebo, and four weeks placebo.</P>
<P>
<LINK REF="STD-QALS-Study-Group-2009" TYPE="STUDY">QALS Study Group 2009</LINK>
</P>
<P>An adaptive, two-stage, bias-adjusted, randomized, placebo controlled, double-blind, phase II study of coenzyme Q10. Coenzyme Q10 at 1800 mg/day and 2700 mg/day</P>
<P>The study was conducted at 19 centres in the USA. Diagnosis was of definite, probable, or laboratory supported probable ALS, sporadic or familial by the El Escorial guidelines.</P>
<P>The primary outcome was decline in the ALS Functional Rating Scale-revised (ALSFRSr) score from baseline to nine months. Secondary outcome measures were decline in forced vital capacity, fatigue severity (9-item fatigue severity scale) and quality of life (SF-36 with physical and mental components analyzed separately). Oxidative stress was assessed in plasma by 8-hydroxy-2 deoxyguanosine measurement.</P>
<P>The design was innovative, aiming to minimize sample size and length of follow-up. In Stage 1, 35 patients were allocated to each of placebo, CoQ10 1800 mg/day and CoQ10 2700 mg/day, for nine months. The dose of 2700 mg/day had higher efficacy, and was chosen for Stage 2. In Stage 2, 40 patients were added to each of the placebo and CoQ10 2700 mg/day groups, and studied for a further nine months.</P>
<P>
<LINK REF="STD-Stevic-2001" TYPE="STUDY">Stevic 2001</LINK>
<BR/>A double-blind, placebo controlled trial of a combination of L-methionine (2 g), vitamin E (400 IU) and selenium (3 x 10-5g) (Alsemet), or placebo, taken orally three times daily.</P>
<P>The study was performed in Yugoslavia. Sixteen patients received medication, and 12 placebo. Randomization was not stated, but implied. The mean age of participants was 57 years. Inclusion criteria were probable or definite ALS by El Escorial criteria, age 20 to 70 years, disease duration of less than 3 years, and ambulatory. Exclusion criteria were significant compromise of bulbar or respiratory function, conduction block, M protein, significant imaging abnormality, dementia, and concurrent systemic disease.</P>
<P>The primary endpoints were survival and rate of disease progression as expressed by decline in limb-function, bulbar-function and muscle testing scores.</P>
<P>The secondary endpoints were the activity of antioxidative components (glutathione peroxidase, glutathione reductase, and catalase) and the level of vitamin E, in blood.</P>
<P>The study was initially presented in abstract form (Stevic 1998) with some difference in results. In Stevic 1998, at 12 months 6/12 patients in the placebo group were alive and 17/20 in the Alsemet group. In Stevic 2001, at 12 months 6/12 in the placebo group were alive but 13/16 were alive in the Alsemet group.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-05-10 19:55:13 +0100" MODIFIED_BY="Ruth Brassington">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Adequate sequence generation and allocation concealment</HEADING>
<P>Sequence generation and allocation concealment were graded unclear in all studies. Explicit details of randomization were not given. In the studies of <LINK REF="STD-Mitchell-1995" TYPE="STUDY">Mitchell 1995</LINK> and Stevic 1998, randomization was not stated but was implied by being double-blind, placebo controlled studies. Professor Mitchell has confirmed that randomization was undertaken within the pharmacy and was completely independent of the researchers.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding (all outcomes)</HEADING>
<P>Blinding was graded adequate in three studies (<LINK REF="STD-Lange-1998" TYPE="STUDY">Lange 1998</LINK>; <LINK REF="STD-Louwerse-1995" TYPE="STUDY">Louwerse 1995</LINK>; <LINK REF="STD-QALS-Study-Group-2009" TYPE="STUDY">QALS Study Group 2009</LINK>), and unclear in eight studies (<LINK REF="STD-Apostolski-1998" TYPE="STUDY">Apostolski 1998</LINK>; <LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK>; <LINK REF="STD-Ellis-1997" TYPE="STUDY">Ellis 1997</LINK>; <LINK REF="STD-Graf-2005" TYPE="STUDY">Graf 2005</LINK>; <LINK REF="STD-Jossan-1994" TYPE="STUDY">Jossan 1994</LINK>; <LINK REF="STD-Mitchell-1995" TYPE="STUDY">Mitchell 1995</LINK>; <LINK REF="STD-Stevic-2001" TYPE="STUDY">Stevic 2001</LINK>). Generally the details of blinding were not clear, although the studies were stated to be blinded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Incomplete outcome data addressed</HEADING>
<P>Incomplete outcome data were adequately addressed in two studies (<LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK>; <LINK REF="STD-QALS-Study-Group-2009" TYPE="STUDY">QALS Study Group 2009</LINK>), but unclear in seven studies (<LINK REF="STD-Apostolski-1998" TYPE="STUDY">Apostolski 1998</LINK>; <LINK REF="STD-Ellis-1997" TYPE="STUDY">Ellis 1997</LINK>; <LINK REF="STD-Graf-2005" TYPE="STUDY">Graf 2005</LINK>; <LINK REF="STD-Jossan-1994" TYPE="STUDY">Jossan 1994</LINK>; <LINK REF="STD-Lange-1998" TYPE="STUDY">Lange 1998</LINK>; <LINK REF="STD-Louwerse-1995" TYPE="STUDY">Louwerse 1995</LINK>; <LINK REF="STD-Mitchell-1995" TYPE="STUDY">Mitchell 1995</LINK>; <LINK REF="STD-Stevic-2001" TYPE="STUDY">Stevic 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Free of selective reporting</HEADING>
<P>Seven studies were graded to be adequately free of selective reporting (<LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK>; <LINK REF="STD-Graf-2005" TYPE="STUDY">Graf 2005</LINK>; <LINK REF="STD-Lange-1998" TYPE="STUDY">Lange 1998</LINK>; <LINK REF="STD-Louwerse-1995" TYPE="STUDY">Louwerse 1995</LINK>; <LINK REF="STD-Mitchell-1995" TYPE="STUDY">Mitchell 1995</LINK>; <LINK REF="STD-QALS-Study-Group-2009" TYPE="STUDY">QALS Study Group 2009</LINK>; <LINK REF="STD-Stevic-2001" TYPE="STUDY">Stevic 2001</LINK>), but unclear in three studies (<LINK REF="STD-Apostolski-1998" TYPE="STUDY">Apostolski 1998</LINK>; <LINK REF="STD-Ellis-1997" TYPE="STUDY">Ellis 1997</LINK>; <LINK REF="STD-Jossan-1994" TYPE="STUDY">Jossan 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Free of other bias</HEADING>
<P>Five studies were graded to be adequately free of other bias (<LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK>; <LINK REF="STD-Lange-1998" TYPE="STUDY">Lange 1998</LINK>; <LINK REF="STD-Louwerse-1995" TYPE="STUDY">Louwerse 1995</LINK>; <LINK REF="STD-QALS-Study-Group-2009" TYPE="STUDY">QALS Study Group 2009</LINK>; <LINK REF="STD-Stevic-2001" TYPE="STUDY">Stevic 2001</LINK>), and four were unclear (<LINK REF="STD-Apostolski-1998" TYPE="STUDY">Apostolski 1998</LINK>; <LINK REF="STD-Ellis-1997" TYPE="STUDY">Ellis 1997</LINK>; <LINK REF="STD-Jossan-1994" TYPE="STUDY">Jossan 1994</LINK>; <LINK REF="STD-Mitchell-1995" TYPE="STUDY">Mitchell 1995</LINK>). One study was graded as not being free of other bias (<LINK REF="STD-Graf-2005" TYPE="STUDY">Graf 2005</LINK>) as seven patients in the placebo group were taking open vitamin E and 23% of patients were taking vitamin E at the onset of the study.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-05-10 22:23:43 +0100" MODIFIED_BY="Ruth Brassington">
<P>There were generally insufficient data for subgroup analysis of individual antioxidants.</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome measures</HEADING>
<P>Only two studies used the primary outcome measure we had proposed in our protocol as their primary measure (<LINK REF="STD-Louwerse-1995" TYPE="STUDY">Louwerse 1995</LINK>; <LINK REF="STD-Stevic-2001" TYPE="STUDY">Stevic 2001</LINK>). One study used this measure as a secondary outcome (<LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK>) and in another the data were given and analyzed in a Kaplan-Meier curve (<LINK REF="STD-Graf-2005" TYPE="STUDY">Graf 2005</LINK>).</P>
<P>
<LINK REF="STD-Louwerse-1995" TYPE="STUDY">Louwerse 1995</LINK> reported that at 12 months, 35 participants (65%) treated with acetylcysteine and 30 participants (54%) given placebo were still alive (hazard ratio (HR) 0.74 in the acetylcysteine group relative to the placebo group; 95% confidence interval (CI) 0.41 to 1.33; log-rank test, P = 0.31). The difference in 12 month survival was 11% in favor of the treated patients (95% CI -30% to 7%). The reported mortality risk reduction was 26% relative to placebo. The effect remained after adjustment for baseline differences in prognostic factors by multivariate analysis, with an adjusted HR of 0.71 (95% CI 0.38 to 1.32). In a subgroup analysis confined to those with limb onset (81 patients), 74% in the treated and 51% in the placebo group survived 12 months (HR 0.50; 95% CI 0.24 to 1.04; P = 0.06); and in bulbar onset (29 patients) 44% in the treated and 62% in the placebo group survived 12 months (HR 1.66; 95% CI 0.56 to 4.99; P = 0.36). In our analysis of survival at 12 months, relative risk was 1.13 (95% CI 0.82 to 1.54) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), and risk difference was 0.07 (95% CI -0.11 to 0.25) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>
<LINK REF="STD-Stevic-2001" TYPE="STUDY">Stevic 2001</LINK> reported that at 12 months, 6/12 (50%) patients in the control group were still alive compared to 13/16 (81%) in the treatment group. Survival was analyzed using the Mantel test. A significant difference in survival (P &lt; 0.05) was reported. In our analysis of survival at 12 months, we found no significant difference. Relative risk was 1.63 (95% CI 0.88 to 3.00) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), and risk difference was 0.31 (95% CI -0.03 to 0.65) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>
<LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK> used survival as a secondary outcome measure. The log-rank test revealed no statistically significant difference (P = 0.89) in survival at 12 months. In our analysis of survival at 12 months, the relative risk was 1.01 (95% CI 0.89 to 1.15) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), and risk difference was 0.01 (95% CI -0.09 to 0.11) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>
<LINK REF="STD-Graf-2005" TYPE="STUDY">Graf 2005</LINK> used time to death as the primary endpoint, but gave data for survival at 360 days (12 months equivalent): 64/83 (77%) survived in the vitamin E group and 53/77 (69%) survived in the placebo group. (The groups appear to be incorrectly labelled in the paper, Figure 1.) Additional data were available for survival at 90, 180, 270, 450 and 540 days (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). The effect of vitamin E just failed to reach significance at six months treatment, and otherwise was not significant.</P>
<P>Meta-analysis of survival at 12 months in these three studies showed no significant effect of treatment. The forest plots are shown in the analysis section. The relative risk was 1.08 (95% CI 0.97 to 1.19) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The risk difference was 0.05 (95% CI -0.02 to 0.13) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). Sensitivity analysis, omitting <LINK REF="STD-Stevic-2001" TYPE="STUDY">Stevic 2001</LINK>, showed a relative risk of 1.06 (95% CI 0.95 to 1.17).</P>
<P>There were insufficient data to perform meta-analysis of functional scales.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcome measures</HEADING>
<P>There were generally insufficient data to pool included studies for secondary outcome measures.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Proportional change in survival as a function of time at 3, 6, 9, 15, 18 months</HEADING>
<P>
<LINK REF="STD-Graf-2005" TYPE="STUDY">Graf 2005</LINK> gave survival numbers at 90, 180, 270, 450 and 540 days (equivalent to 3, 6, 9, 15 and 18 months). (The data appear to be incorrectly labelled in the original paper.) No significant difference was reported between placebo and treatment group with the stratified log-rank test or stratified Wilcoxon test. The HR was calculated as 1.145 (95% CI 0.701 to 1.872).</P>
<P>
<LINK REF="STD-Louwerse-1995" TYPE="STUDY">Louwerse 1995</LINK> and <LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK> published Kaplan-Meier survival curves for a 12 month period, but with no data on individual time points other than at 12 months, as above. Desnuelle 2001 reported that the log-rank test revealed no significant difference between treated and placebo groups (P = 0.89).</P>
<P>
<LINK REF="STD-Lange-1998" TYPE="STUDY">Lange 1998</LINK> reported that 4 of 67 participants died in the treatment group, and 3 of 66 participants died in the placebo group over six months. A 'survival function estimate' was plotted over six months, with patients censored at a progression of 22 points in AALS total score. Using this endpoint, no significant difference was reported between the two groups: Wilcoxon<SUP>2</SUP> = 0.01, P = 0.98.</P>
<P>
<LINK REF="STD-Stevic-2001" TYPE="STUDY">Stevic 2001</LINK> produced a Kaplan-Meier survival curve over 12 months but with absolute values given only for the 12 month point.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Duration of disease</HEADING>
<P>
<LINK REF="STD-Graf-2005" TYPE="STUDY">Graf 2005</LINK> used duration of disease as the primary endpoint. Thirty-two participants from each group reached the endpoint by the end of the study (18 months). In the vitamin E group the duration was 315 + 13 days and in the placebo group it was 278 + 15 days. Statistical analysis was not given. There was stated to be no significant difference using the stratified log-rank test or the Wilcoxon test.</P>
<P>The other studies were not designed to measure duration of disease, which is probably not an appropriate or realistic measure in initial studies of therapy of ALS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Quantitative muscle testing (12 and 18 months)</HEADING>
<P>
<LINK REF="STD-Louwerse-1995" TYPE="STUDY">Louwerse 1995</LINK> found no significant difference in linear rate of decline in myometric and manually tested muscle strength during 12 months. In a subgroup analysis of bulbar onset patients (16 acetylcysteine, 13 placebo) there was an increased deterioration in muscle strength measured by the MRC score (P &lt; 0.01) and myometry (P &lt; 0.01) in patients receiving acetylcysteine.</P>
<P>
<LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK> found no significant difference in muscle testing at 12 months.</P>
<P>
<LINK REF="STD-Graf-2005" TYPE="STUDY">Graf 2005</LINK> states that manual muscle testing was performed, but no data were given.</P>
<P>
<LINK REF="STD-Mitchell-1995" TYPE="STUDY">Mitchell 1995</LINK> in a cross-over study with 16 weeks treatment found no significant difference in hand-held myometry of a range of muscles; and hand grip. It was commented that selegiline may "hold" some of the indices of disease progression in ALS and that there may also be a "carry over" effect persisting several months after selegiline was stopped.</P>
<P>
<LINK REF="STD-Stevic-2001" TYPE="STUDY">Stevic 2001</LINK> published bar charts indicating that the rate of deterioration of muscle testing scores was significantly slower in treated patients (P &lt; 0.025) at six months, but with no difference at 12 months. Absolute values were not given.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Functional rating scales (12 and 18 months)</HEADING>
<P>
<LINK REF="STD-Apostolski-1998" TYPE="STUDY">Apostolski 1998</LINK> reported progression in Norris score in all subgroups, but an improvement in the Alsamin group. No statistical analysis was performed.</P>
<P>
<LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK> found no significant difference in Norris limb score at 12 months. The ALS Health State scale (AHSS), which has the four states I to IV, was used. States I and II were combined as State A, and States III and IV as State B. In the control group 53 patients (44.5%) progressed from AHSS State A to AHSS State B compared to only 39 patients (32%) in the treated group, over 12 months (P = 0.04).<BR/>
<BR/>
<LINK REF="STD-Ellis-1997" TYPE="STUDY">Ellis 1997</LINK>, in a six months treatment study preceded by six months observation, found that three of five patients in the treatment group had a slower rate of change of Appel Rating Scale (ARS) during treatment versus the observation period; three of five patients in the placebo group had a faster rate of change. However, using a mixed model analysis of variance which considered treatment group, treatment period, and visits interactions there was no statistically significant effect of treatment on ARS.</P>
<P>
<LINK REF="STD-Graf-2005" TYPE="STUDY">Graf 2005</LINK> stated that "Functional assessments according to the scales showed a trend in favour of vitamin E without however reaching significance". Data for the Norris limb score was given as an example.</P>
<P>
<LINK REF="STD-Lange-1998" TYPE="STUDY">Lange 1998</LINK> found no difference in the rate of progression as measured by the Appel ALS total score over six months. The monthly rate of change was 3.4 for the treated group, and 3.5 for the control group.</P>
<P>
<LINK REF="STD-Louwerse-1995" TYPE="STUDY">Louwerse 1995</LINK> found no significant difference in pulmonary function at 12 months. There was no significant difference in bulbar function scale score. In a subgroup analysis of bulbar onset patients, there was an increased deterioration in bulbar function (P &lt; 0.01) in patients receiving acetylcysteine.</P>
<P>
<LINK REF="STD-Jossan-1994" TYPE="STUDY">Jossan 1994</LINK>, in a cross-over study with 12 weeks on treatment, found no statistically significant difference in Norris, spinal and bulbar scores.</P>
<P>
<LINK REF="STD-Mitchell-1995" TYPE="STUDY">Mitchell 1995</LINK>, in a cross-over study with 16 weeks on treatment, found no significant difference in bulbar rating scale.</P>
<P>
<LINK REF="STD-Stevic-2001" TYPE="STUDY">Stevic 2001</LINK> stated that the deterioration of limb and bulbar function scores was significantly lower in treated than control groups at six months (P &lt; 0.05) but not at 12 months. Bar charts of the results were presented but no absolute values were given. The linear rate of decline was not given.</P>
<P>
<LINK REF="STD-QALS-Study-Group-2009" TYPE="STUDY">QALS Study Group 2009</LINK> found no significant difference in mean decline of ALSFRSr over a nine month period. There was no significant difference in decline of FVC (% of predicted).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Subjective rating scales (12 and 18 months)</HEADING>
<P>
<LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK> found no significant difference in self assessed scoring of cramps, fatigue, stiffness, or fasciculations at 12 months.</P>
<P>
<LINK REF="STD-Louwerse-1995" TYPE="STUDY">Louwerse 1995</LINK> found no significant difference in ability to perform activities of daily living (disability) by the Barthel Index and overall degree of independence (handicap) by the modified Rankin Scale, at 12 months.</P>
<P>
<LINK REF="STD-Mitchell-1995" TYPE="STUDY">Mitchell 1995</LINK>, in a cross-over study with 16 weeks on treatment, found no significant difference in the Barthel Disability Index and Rankin Disability Scale.</P>
<P>
<LINK REF="STD-QALS-Study-Group-2009" TYPE="STUDY">QALS Study Group 2009</LINK> found no significant difference in fatigue severity measured by the nine-item fatigue severity scale (FSS) over a nine month period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Quality of life assessments of patients and caregivers (12 and 18 months)</HEADING>
<P>
<LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK> found no difference in quality of life as measured by the Sickness Impact Profile (SIP) at 12 months. This appeared to relate to patients only, and not caregivers.</P>
<P>
<LINK REF="STD-Graf-2005" TYPE="STUDY">Graf 2005</LINK> measured the Sickness Impact Profile, but no data were given.</P>
<P>
<LINK REF="STD-Mitchell-1995" TYPE="STUDY">Mitchell 1995</LINK>, in a cross-over study with 16 weeks on treatment, found no significant difference in the quality of life scale. This appeared to relate to patients only, and not caregivers.</P>
<P>
<LINK REF="STD-QALS-Study-Group-2009" TYPE="STUDY">QALS Study Group 2009</LINK> found no significant difference in physical or mental components of quality of life, measured by SF-36-PCS and SF-36-MCS, over a nine month period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Adverse effects</HEADING>
<P>
<LINK REF="STD-Louwerse-1995" TYPE="STUDY">Louwerse 1995</LINK> reported three patients discontinuing the study with rashes and pain at the injection site. All three were receiving acetylcysteine. No other adverse effects were documented.</P>
<P>
<LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK> reported adverse events: 74.3% in the control group, and 80.5% in the treatment group. Forty-two per cent were classified as serious. There was no statistically significant difference between the two groups. There was no common adverse event that could be unambiguously attributed to treatment with a-tocopherol.</P>
<P>
<LINK REF="STD-Lange-1998" TYPE="STUDY">Lange 1998</LINK> reported one patient requiring a reduction in dose with subsequent withdrawal because of worsening depression.</P>
<P>
<LINK REF="STD-Stevic-2001" TYPE="STUDY">Stevic 2001</LINK> stated that L-methionine, vitamin E and selenium (Alsemet) were well tolerated and no adverse effects were observed.</P>
<P>
<LINK REF="STD-QALS-Study-Group-2009" TYPE="STUDY">QALS Study Group 2009</LINK> reported no serious adverse events related to coenzyme Q10. There was no significant difference in adverse events between the placebo and coenzyme Q10 groups.</P>
<P>
<LINK REF="STD-Jossan-1994" TYPE="STUDY">Jossan 1994</LINK>; <LINK REF="STD-Mitchell-1995" TYPE="STUDY">Mitchell 1995</LINK> and <LINK REF="STD-Ellis-1997" TYPE="STUDY">Ellis 1997</LINK> did not report adverse effects.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-05-10 19:58:16 +0100" MODIFIED_BY="Ruth Brassington">
<P>Of the 10 included studies only four provided sufficient data for analysis of the primary endpoint, survival at 12 months. The results of the individual studies, and the meta-analysis, showed no benefit of the individual antioxidants vitamin E (<LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK>), acetylcysteine (<LINK REF="STD-Louwerse-1995" TYPE="STUDY">Louwerse 1995</LINK>) and a combination of L-methionine, vitamin E, and selenium (Alsemet) (<LINK REF="STD-Stevic-2001" TYPE="STUDY">Stevic 2001</LINK>). Significant differences in trial methodology and the selection of primary and secondary measures and endpoints caused difficulty in comparing studies, pooling results and performing meta-analysis. <LINK REF="STD-QALS-Study-Group-2009" TYPE="STUDY">QALS Study Group 2009</LINK> used an adaptive trial design aiming for a more efficient phase II study design <LINK REF="REF-Cudkowicz-2010" TYPE="REFERENCE">Cudkowicz 2010</LINK>.</P>
<P>
<LINK REF="STD-Stevic-2001" TYPE="STUDY">Stevic 2001</LINK> reported significantly improved survival at 12 months using a combination of selegiline, selenium and methionine (not necessarily an antioxidant). This was a small study of 28 patients and the method of randomization was not clear. A Mantel test was used for statistical analysis. We did not find a significant improvement in survival at 12 months using our analyses of relative risk and risk difference. A further study with a larger number of patients and standardized trial methodology would be interesting. Methionine itself may deserve further study to clarify the effect. <LINK REF="STD-Apostolski-1998" TYPE="STUDY">Apostolski 1998</LINK> reported an improvement in Norris score over 63 days treatment with Alsamin in seven patients. No statistical analysis was performed and the result is difficult to interpret. A more rigorous study of a larger number of patients over a longer period of time is required to prove efficacy.</P>
<P>The antioxidant medications used are generally well tolerated and without serious adverse effects. This probably explains their wide use by patients, with or without the advice of their physician. This is especially so when faced with a rapidly progressive, fatal condition for which there is no dramatically effective therapy. The effect of riluzole is mild, and its sole potential effect in marginally extending survival is not apparent to the individual patient. A recent meta-analysis of high dosage vitamin E supplementation in a variety of conditions reported an increased all cause adverse mortality risk difference of 39 per 100,000, and concluded that high dosage vitamin E (&gt; 400 IU/day) should be avoided (<LINK REF="REF-Greenberg-2005" TYPE="REFERENCE">Greenberg 2005</LINK>; <LINK REF="REF-Miller-2005" TYPE="REFERENCE">Miller 2005</LINK>). This may have importance for long-term preventive intake but is unlikely to be of significance in a rapidly progressive and fatal condition such as ALS. Another recent study (<LINK REF="STD-Ascherio-2005" TYPE="STUDY">Ascherio 2005</LINK>) concluded that individuals participating in the American Cancer Society's Cancer Prevention Study II, who were taking regular vitamin E supplementation of an undefined dose for 10 years or more, had a reduced age and smoking adjusted relative risk of dying of ALS of 0.38. There was no effect of vitamin C or multivitamins. It was suggested that vitamin E supplementation may have a role in ALS prevention. This is an important observation on the potential benefit of antioxidants in preventing onset of ALS but the study was not a randomized controlled trial of treatment of ALS and did not fulfil the criteria for inclusion in this systematic review. Another study (<LINK REF="REF-Veldink-2007" TYPE="REFERENCE">Veldink 2007</LINK>) assessed whether the premorbid dietary intake of fatty acids, cholesterol, glutamate or antioxidants was associated with the risk of developing ALS. This was assessed using a food-frequency questionnaire. The authors concluded that a high intake of polyunsaturated fatty acid and vitamin E was associated with a 50% to 60% decreased risk of developing ALS, and they appeared to act synergistically. Intake of flavanols, lycopene, vitamin C, vitamin B2, glutamate, calcium and phytoestrogens was not associated with the risk of developing ALS.</P>
<P>Many of the antioxidants are readily available, often without prescription. We did not, however, find any evidence to support the use of these medications on the basis of well-designed, randomized controlled trials. The cost of the individual medication is relatively low but may vary depending on the formulation used. For example, <LINK REF="REF-Pioro-2000" TYPE="REFERENCE">Pioro 2000</LINK> recommended the following antioxidant therapies for ALS "on the basis of available data and documented toxicities":<BR/>
</P>
<UL>
<LI>people with ALS should avoid activities that reduce endogenous antioxidant levels; for example smoking, which reduces serum vitamin C concentrations;</LI>
<LI>high dose vitamin E (up to 2000 IU/day);</LI>
<LI>high dose vitamin C (500 to 1000 mg/day);</LI>
<LI>consideration of catalase, trientine and lipoic acid, on the basis of animal model studies and low toxicity.</LI>
</UL>
<P>The approximate current daily cost of vitamin E 1000 IU is from GBP 0.30, and vitamin C 1000 mg is from GBP 0.05. For comparison, the approximate daily cost of riluzole 50 mg twice daily is GBP 10.00.</P>
<P>Although the use of vitamins C and E for the treatment of ALS is not supported by clinical trial data, the high tolerance and safety, relatively low cost, and ready availability do not contraindicate their common usage by physicians and patients. This may be an important consideration when other unproven medications may have a higher potential risk of adverse effects, and higher cost.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-05-10 19:58:27 +0100" MODIFIED_BY="Ruth Brassington">
<IMPLICATIONS_PRACTICE MODIFIED="2011-05-10 19:58:18 +0100" MODIFIED_BY="Ruth Brassington">
<P>We conclude that despite substantial literature on the potential scientific basis for the use of antioxidants in people with ALS and the widespread use of these medications by patients, often on the advice of their physician, there is no significant evidence that they have a beneficial effect in people with ALS.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-05-10 19:58:27 +0100" MODIFIED_BY="Ruth Brassington">
<P>The quality of design and presentation of the earlier studies was generally poor. Methodology was often incompletely described. The studies were generally underpowered to prove any benefit which may be present, especially when compared to the studies of riluzole, which are the only studies so far to have demonstrated benefit from a therapeutic agent in people with ALS. The most recent studies show improved trial design, and novel approaches.<U>
<BR/>
</U>
<BR/>In future, it is important that the patient entry characteristics are well defined and, if possible, comparable between trials. Inclusion and exclusion criteria should be defined. There should be some conformity in outcome measures and primary outcome measures should be defined. Adverse effects require more detailed description. In addition to survival or functional measures, quality of life measures should be included.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-05-10 19:58:30 +0100" MODIFIED_BY="Ruth Brassington">
<P>Translator: Anna Wanstead, Wellcome Institute.</P>
<P>Translator: Muke Zhou.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Dr Orrell led the design of the review, collation and analysis of the studies, and the writing of the review. Dr Lane and Dr Ross contributed to the design of the review, analysis of the studies, and writing of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-05-10 22:07:05 +0100" MODIFIED_BY="Ruth Brassington">
<STUDIES MODIFIED="2011-05-10 22:04:08 +0100" MODIFIED_BY="Ruth Brassington">
<INCLUDED_STUDIES MODIFIED="2011-05-10 19:59:14 +0100" MODIFIED_BY="Ruth Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-Apostolski-1998" MODIFIED="2011-03-01 14:57:12 +0000" MODIFIED_BY="Kate Jewitt" NAME="Apostolski 1998" YEAR="">
<REFERENCE MODIFIED="2011-03-01 14:57:12 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Apostolski S, Markinkovic Z, Nocolic A, Blagojevic D, Spasic MB, Michelson AM</AU>
<TI>Glutathione peroxidase in amyotrophic lateral sclerosis: the effects of selenium supplementation</TI>
<SO>Journal of Environmental Pathology, Toxicology and Oncology</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>3-4</NO>
<PG>325-9</PG>
<IDENTIFIERS MODIFIED="2011-03-01 14:57:12 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 14:57:12 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="9726810"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Desnuelle-2001" MODIFIED="2011-05-10 19:58:52 +0100" MODIFIED_BY="Ruth Brassington" NAME="Desnuelle 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-05-10 19:58:52 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Desnuelle C, Dib M, Garrel C, Favier A. ALS riluzole-tocopherol Study Group</AU>
<TI>A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis</TI>
<SO>Amyotrophic Lateral Sclerosis and other motor neuron disorders</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>1</NO>
<PG>9-18</PG>
<IDENTIFIERS MODIFIED="2011-03-01 14:57:34 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 14:57:34 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="11465936"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ellis-1997" NAME="Ellis 1997" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ellis T, Cudkowicz ME, McKenna-Yasek D, Eggelston PM, Brown RH, Cros D</AU>
<TI>Combination antioxidant therapy in amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>48</VL>
<PG>A127</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graf-2005" MODIFIED="2011-05-10 19:59:05 +0100" MODIFIED_BY="Ruth Brassington" NAME="Graf 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-05-10 19:59:05 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graf M, Ecker D, Horowski R, Kramer B, Riederer P, Gerlach M et al, on behalf of the German Vitamin E / ALS Study Group</AU>
<TI>High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study</TI>
<SO>Journal of Neurotransmission</SO>
<YR>2005</YR>
<VL>112</VL>
<NO>5</NO>
<PG>649-60</PG>
<IDENTIFIERS MODIFIED="2011-03-01 14:58:10 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 14:58:10 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="15517433"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jossan-1994" MODIFIED="2011-05-10 19:59:14 +0100" MODIFIED_BY="Ruth Brassington" NAME="Jossan 1994" YEAR="">
<REFERENCE MODIFIED="2011-05-10 19:59:14 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jossan SS, Ekblom J, Gudjonsson O, Hagbarth KE, Aquilonius SM</AU>
<TI>Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis</TI>
<SO>Journal of Neural Transmission</SO>
<YR>1994</YR>
<VL>41 Suppl</VL>
<PG>237-41</PG>
<IDENTIFIERS MODIFIED="2011-03-01 14:58:59 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 14:58:59 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7931231"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lange-1998" MODIFIED="2011-03-01 14:59:16 +0000" MODIFIED_BY="Kate Jewitt" NAME="Lange 1998" YEAR="">
<REFERENCE MODIFIED="2011-03-01 14:59:16 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lange DJ, Murphy PL, Diamond B, Appel V, Lai EC, Younger DS et al</AU>
<TI>Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1998</YR>
<VL>55</VL>
<NO>1</NO>
<PG>93-6</PG>
<IDENTIFIERS MODIFIED="2011-03-01 14:59:16 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 14:59:16 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="9443715"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Louwerse-1995" MODIFIED="2011-03-01 14:59:34 +0000" MODIFIED_BY="Kate Jewitt" NAME="Louwerse 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-03-01 14:59:34 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Louwerse ES, Weverling GJ, Bosuyt PM, Meyjes FE, De Jong JM</AU>
<TI>Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1995</YR>
<VL>52</VL>
<NO>6</NO>
<PG>559-64</PG>
<IDENTIFIERS MODIFIED="2011-03-01 14:59:34 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 14:59:34 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7763202"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitchell-1995" MODIFIED="2011-03-01 14:59:57 +0000" MODIFIED_BY="Kate Jewitt" NAME="Mitchell 1995" YEAR="">
<REFERENCE MODIFIED="2011-03-01 14:59:57 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell JD, Gatt JA, Phillips TM, Houghton E, Rostron G, Wignall C</AU>
<TI>Cu/Zn superoxide dismutase free radicals, and motoneuron disease [Letter]</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>342</VL>
<NO>8878</NO>
<PG>1051-2</PG>
<IDENTIFIERS MODIFIED="2011-03-01 14:59:57 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 14:59:57 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8105281"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell JD, Houghton E, Rostron G, Wignall C, Gatt JA, Phillips TM et al</AU>
<TI>Serial studies of free radical and antioxidant activity in motor neurone disease and the effect of selegiline [letter]</TI>
<SO>Neurodegeneration</SO>
<YR>1995</YR>
<VL>4</VL>
<NO>2</NO>
<PG>233-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Mitchell JD, Houghton E, Rostron G, Wignall C, Phillips TM, Kilshaw J</AU>
<TI>Indices of free radical and antioxidant activity in amyotrophic lateral sclerosis</TI>
<SO>ALS - from Charcot to the present and into the future</SO>
<YR>1994</YR>
<PG>297-307</PG>
<ED>Clifford Rose F</ED>
<PB>Smith-Gordon and Company Ltd</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-QALS-Study-Group-2009" MODIFIED="2011-03-28 10:50:02 +0100" MODIFIED_BY="Kate Jewitt" NAME="QALS Study Group 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-03-28 10:50:02 +0100" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS et al</AU>
<TI>Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III</TI>
<SO>Annals of Neurology</SO>
<YR>2009</YR>
<VL>66</VL>
<NO>2</NO>
<PG>235-44</PG>
<IDENTIFIERS MODIFIED="2011-03-01 14:00:48 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 14:00:48 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="19743457"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stevic-2001" NAME="Stevic 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stevic Z, Nicolic A, Blagjevic D, Saicia ZS, Kocev N, Apostolski S et al</AU>
<TI>A controlled trial of combination of methionine and antioxidants in ALS patients</TI>
<SO>Jugoslavenska Medicinska Biokemija</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>223-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Stevic Z, Nicolic A, Blagojevic D, Saicic ZS, Apolstolski S, Spasic M</AU>
<TI>A controlled trial of combination of methionine and antioxidants in amyotrophic lateral sclerosis</TI>
<SO>Proceedings ALS/MND International Alliance Meeting, Munich, Germany</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-05-10 22:04:08 +0100" MODIFIED_BY="Ruth Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-Ascherio-2005" MODIFIED="2011-05-10 22:04:08 +0100" MODIFIED_BY="Ruth Brassington" NAME="Ascherio 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-05-10 22:04:08 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ascherio A, Weisskopf MG, O'Reilly EJ, Jacobs EJ, McCullough ML, Calle EE et al</AU>
<TI>Vitamin E intake and risk of amyotrophic lateral sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>2005</YR>
<VL>57</VL>
<NO>1</NO>
<PG>104-10</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:00:40 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:00:40 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="15529299"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chio-1998" MODIFIED="2011-03-01 15:01:05 +0000" MODIFIED_BY="Kate Jewitt" NAME="Chio 1998" YEAR="">
<REFERENCE MODIFIED="2011-03-01 15:01:05 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chio A, Cucatto A, Terreni AA, Schiffer D</AU>
<TI>Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial</TI>
<SO>Italian Journal of Neurological Science</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>6</NO>
<PG>363-6</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:01:05 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:01:05 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="10935831"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dorman-1969" MODIFIED="2011-03-01 15:01:37 +0000" MODIFIED_BY="Kate Jewitt" NAME="Dorman 1969" YEAR="">
<REFERENCE MODIFIED="2011-03-01 15:01:37 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dorman JD, Engel WK, Fried DM</AU>
<TI>Therapeutic trial in amyotrophic lateral sclerosis</TI>
<SO>JAMA</SO>
<YR>1969</YR>
<VL>209</VL>
<NO>2</NO>
<PG>257-8</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:01:37 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:01:37 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="5819254"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Engel WK, Hogenhuis LAH, Collis WJ, Schalch DS, Barlow MH, Gold GN et al</AU>
<TI>Metabolic studies and therapeutic trials in amyotrophic lateral sclerosis</TI>
<SO>Motor neuron diseases</SO>
<YR>1969</YR>
<PG>199-208</PG>
<ED>Norris FH, Kurland LT</ED>
<PB>Grune and Stratton</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janik-1996" MODIFIED="2011-05-10 20:00:05 +0100" MODIFIED_BY="Ruth Brassington" NAME="Janik 1996" YEAR="">
<REFERENCE MODIFIED="2011-05-10 19:59:33 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Janik P, Kwiecinski H, Jamrozik Z, Czyzewski K, Opuchlik A</AU>
<TI>A randomised trial of antioxidative therapy in amyotrophic lateral sclerosis</TI>
<SO>Journal of Neurology</SO>
<YR>1996</YR>
<VL>243 Suppl</VL>
<PG>25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-05-10 20:00:05 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kwiecinski H, Janik P, Jamrozik Z, Opuchlik A</AU>
<TI>The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trial [Polish]</TI>
<SO>Neurologia i Neurochirurgia Polska</SO>
<YR>2001</YR>
<VL>Suppl 1</VL>
<PG>101-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mazzini-1994" MODIFIED="2011-03-01 15:02:00 +0000" MODIFIED_BY="Kate Jewitt" NAME="Mazzini 1994" YEAR="">
<REFERENCE MODIFIED="2011-03-01 15:02:00 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mazzini L, Testa D, Balzarini C, Mora G</AU>
<TI>An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis</TI>
<SO>Journal of Neurology</SO>
<YR>1994</YR>
<VL>241</VL>
<NO>4</NO>
<PG>223-7</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:02:00 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:02:00 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8195821"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Norris-1987" MODIFIED="2011-03-01 15:02:19 +0000" MODIFIED_BY="Kate Jewitt" NAME="Norris 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-03-01 15:02:19 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Norris FH, Denys EH</AU>
<TI>Nutritional supplements in amyotrophic lateral sclerosis</TI>
<SO>Advances in Experimental Medicine and Biology</SO>
<YR>1987</YR>
<VL>209</VL>
<PG>183-9</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:02:19 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:02:19 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="3554909"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quick-1969" MODIFIED="2011-03-01 14:13:54 +0000" MODIFIED_BY="Kate Jewitt" NAME="Quick 1969" YEAR="">
<REFERENCE MODIFIED="2011-03-01 14:13:54 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Quick DT</AU>
<TI>Pancreatic dysfunction in amyotrophic lateral sclerosis</TI>
<SO>Motor neuron diseases</SO>
<YR>1969</YR>
<PG>189-98</PG>
<ED>Norris FH, Kurland LT</ED>
<PB>Grune and Stratton</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szczudlik-1998" NAME="Szczudlik 1998" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Szczudilk A, Tomi B, Slowik A, Kasprzyk K</AU>
<TI>Assessment of the efficacy of treatment with pimozide in patients with amyotrophic lateral sclerosis</TI>
<SO>Neurologia i Neurochirurgia Polska</SO>
<YR>1998</YR>
<VL>T32</VL>
<NO>XLVIII</NO>
<PG>821-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vyth-1996" MODIFIED="2011-03-01 15:02:45 +0000" MODIFIED_BY="Kate Jewitt" NAME="Vyth 1996" YEAR="">
<REFERENCE MODIFIED="2011-03-01 15:02:45 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vyth A, Timmer JG, Bossuyt PMM, Louwerse ES, de Jong JM</AU>
<TI>Survival in patients with amyotrophic lateral sclerosis treated with an array of antioxidants</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1996</YR>
<VL>39 Suppl</VL>
<PG>99-103</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:02:45 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:02:45 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8899667"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wechsler-1940" NAME="Wechsler 1940" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wechsler IS</AU>
<TI>The treatment of amyotrophic lateral sclerosis with vitamin E (tocopherols)</TI>
<SO>American Journal of Medical Science</SO>
<YR>1940</YR>
<VL>200</VL>
<PG>765-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2007" MODIFIED="2011-05-10 20:00:17 +0100" MODIFIED_BY="Ruth Brassington" NAME="Zhang 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-05-10 20:00:17 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang YJ, Zhang J, Zhang N, Zhang HG, Wang LP, Lu M et al</AU>
<TI>The randomized open clinical trial on a novel free radical scavenger edaravone in amyotrophic lateral sclerosis</TI>
<SO>Chinese Journal of Contemporary Neurology and Neurosurgery</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>161-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-05-10 22:07:05 +0100" MODIFIED_BY="Ruth Brassington">
<ADDITIONAL_REFERENCES MODIFIED="2011-05-10 22:07:05 +0100" MODIFIED_BY="Ruth Brassington">
<REFERENCE ID="REF-Beckman-1993" MODIFIED="2011-03-01 15:03:16 +0000" MODIFIED_BY="Kate Jewitt" NAME="Beckman 1993" TYPE="JOURNAL_ARTICLE">
<AU>Beckman JS, Carson M, Smith CD, Koppenol WH</AU>
<TI>ALS, SOD and peroxynitrite</TI>
<SO>Nature</SO>
<YR>1993</YR>
<VL>364</VL>
<NO>6438</NO>
<PG>584</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:03:16 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:03:16 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8350919"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bergeron-1996" NAME="Bergeron 1996" TYPE="BOOK_SECTION">
<AU>Bergeron C, Petrunka C, Weyer L</AU>
<TI>Oxidative stress plays a role in the pathogenesis of familial and sporadic amyotrophic lateral sclerosis</TI>
<SO>Neurodegenerative Diseases</SO>
<YR>1996</YR>
<PG>275-80</PG>
<ED>Fiskum G</ED>
<PB>Plenum Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brooks-1994" MODIFIED="2011-03-01 15:04:15 +0000" MODIFIED_BY="Kate Jewitt" NAME="Brooks 1994" TYPE="JOURNAL_ARTICLE">
<AU>Brooks BR</AU>
<TI>El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1994</YR>
<VL>124 Suppl</VL>
<PG>96-107</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:04:15 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:04:15 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7807156"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cudkowicz-2010" MODIFIED="2011-03-28 10:48:56 +0100" MODIFIED_BY="Kate Jewitt" NAME="Cudkowicz 2010" TYPE="JOURNAL_ARTICLE">
<AU>Cudkowicz ME, Katz J, Moore DH, O'Neill G, Glass JD, Mitsumoto H et al</AU>
<TI>Toward more efficient clinical trials for amyotrophic lateral sclerosis</TI>
<SO>Amyotrophic Lateral Sclerosis</SO>
<YR>2010</YR>
<VL>11</VL>
<NO>3</NO>
<PG>259-65</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:04:58 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:04:58 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="19961263"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Eisen-1998" NAME="Eisen 1998" TYPE="BOOK">
<AU>Eisen A, Krieger C</AU>
<SO>Amyotrophic lateral sclerosis: a synthesis of research and clinical practice</SO>
<YR>1998</YR>
<ED>Eisen A, Krieger C</ED>
<PB>Cambridge University Press</PB>
<CY>Cambridge</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenberg-2005" MODIFIED="2011-03-01 15:05:20 +0000" MODIFIED_BY="Kate Jewitt" NAME="Greenberg 2005" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg ER</AU>
<TI>Vitamin E supplements: good in theory, but is the theory good?</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>142</VL>
<NO>1</NO>
<PG>75-6</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:05:20 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:05:20 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="15579660"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gurney-1996" MODIFIED="2011-03-01 15:05:38 +0000" MODIFIED_BY="Kate Jewitt" NAME="Gurney 1996" TYPE="JOURNAL_ARTICLE">
<AU>Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK</AU>
<TI>Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>1996</YR>
<VL>39</VL>
<NO>2</NO>
<PG>147-57</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:05:38 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:05:38 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8967745"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Halliwell-2001" MODIFIED="2011-03-01 15:06:05 +0000" MODIFIED_BY="Kate Jewitt" NAME="Halliwell 2001" TYPE="JOURNAL_ARTICLE">
<AU>Halliwell B</AU>
<TI>Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment</TI>
<SO>Drugs and Aging</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>6</NO>
<PG>685-716</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:06:05 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:06:05 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="11599633"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2011-05-10 20:00:33 +0100" MODIFIED_BY="Ruth Brassington" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ince-1994" MODIFIED="2011-05-10 22:04:34 +0100" MODIFIED_BY="Ruth Brassington" NAME="Ince 1994" TYPE="JOURNAL_ARTICLE">
<AU>Ince PG, Shaw PJ, Candy JM, Mantle D, Tandon L, Ehmann WD et al</AU>
<TI>Iron, selenium and glutathione peroxidase activity are elevated in sporadic motor neuron disease</TI>
<SO>Neuroscience Letters</SO>
<YR>1994</YR>
<VL>182</VL>
<NO>1</NO>
<PG>87-90</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:06:42 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:06:42 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7891897"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Knoll-1989" MODIFIED="2011-03-01 15:07:00 +0000" MODIFIED_BY="Kate Jewitt" NAME="Knoll 1989" TYPE="JOURNAL_ARTICLE">
<AU>Knoll J</AU>
<TI>The pharmacology of selegiline ((-)deprenyl). New aspects</TI>
<SO>Acta Neurologica Scandinavica. Supplementum</SO>
<YR>1989</YR>
<VL>126</VL>
<PG>83-91</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:07:00 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:07:00 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="2515725"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lacomblez-1996" MODIFIED="2011-03-01 15:07:29 +0000" MODIFIED_BY="Kate Jewitt" NAME="Lacomblez 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Menninger V, The ALS/Riluzole Study Group II</AU>
<TI>A dose-ranging study of riluzole in amyotrophic lateral sclerosis</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>347</VL>
<NO>9013</NO>
<PG>1425-31</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:07:29 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:07:29 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8676624"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Logroscino-2005" MODIFIED="2011-05-10 20:00:55 +0100" MODIFIED_BY="Ruth Brassington" NAME="Logroscino 2005" TYPE="JOURNAL_ARTICLE">
<AU>Logroscino G, Beghi E, Zoccolella S, Palagano R, Fraddosio A, Simone IL et al, the SLAP registry</AU>
<TI>Incidence of amyotrophic lateral sclerosis in southern Italy: a population based study</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>2005</YR>
<VL>76</VL>
<NO>8</NO>
<PG>1094-8</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:07:47 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:07:47 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="15956808"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Miller-2005" MODIFIED="2011-03-01 15:08:27 +0000" MODIFIED_BY="Kate Jewitt" NAME="Miller 2005" TYPE="JOURNAL_ARTICLE">
<AU>Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E</AU>
<TI>Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>142</VL>
<PG>37-46</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:08:27 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:08:27 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="15537632"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Miller-2007" MODIFIED="2011-05-10 22:07:05 +0100" MODIFIED_BY="Ruth Brassington" NAME="Miller 2007" TYPE="COCHRANE_REVIEW">
<AU>Miller RG, Mitchell JD, Moore DH</AU>
<TI>Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<PB>John Wiley and Sons, Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS MODIFIED="2011-05-10 22:07:05 +0100" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2011-05-10 22:07:05 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001447.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mitchell-1987" MODIFIED="2011-03-01 15:08:50 +0000" MODIFIED_BY="Kate Jewitt" NAME="Mitchell 1987" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell JD</AU>
<TI>Heavy metals and trace elements in amyotrophic lateral sclerosis</TI>
<SO>Neurology Clinics</SO>
<YR>1987</YR>
<VL>5</VL>
<NO>1</NO>
<PG>43-60</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:08:50 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:08:50 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="3550416"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Orrell-2006" MODIFIED="2011-03-01 15:11:35 +0000" MODIFIED_BY="Kate Jewitt" NAME="Orrell 2006" TYPE="JOURNAL_ARTICLE">
<AU>Orrell RW</AU>
<TI>AEOL-10150 (Aeolus)</TI>
<SO>Current Opinion in Investigational Drugs</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>1</NO>
<PG>70-80</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:11:35 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:11:35 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="16425674"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pioro-2000" MODIFIED="2011-03-01 15:11:59 +0000" MODIFIED_BY="Kate Jewitt" NAME="Pioro 2000" TYPE="JOURNAL_ARTICLE">
<AU>Pioro EP</AU>
<TI>Antioxidant therapy in ALS</TI>
<SO>ALS and other motor neuron disorders</SO>
<YR>2000</YR>
<VL>1 Suppl 4</VL>
<PG>5-12</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:11:59 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:11:59 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="11466960"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rosen-1993" MODIFIED="2011-03-01 15:12:27 +0000" MODIFIED_BY="Kate Jewitt" NAME="Rosen 1993" TYPE="JOURNAL_ARTICLE">
<AU>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al</AU>
<TI>Mutations in CuZn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis</TI>
<SO>Nature</SO>
<YR>1993</YR>
<VL>362</VL>
<NO>6415</NO>
<PG>59-62</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:12:27 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:12:27 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8446170"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sardesi-1995" NAME="Sardesi 1995" TYPE="JOURNAL_ARTICLE">
<AU>Sardesai VM</AU>
<TI>Role of antioxidants in health maintenance</TI>
<SO>Nutrition in Clinical Practice</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>1</NO>
<PG>19-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sejvar-2005" MODIFIED="2011-03-01 15:13:11 +0000" MODIFIED_BY="Kate Jewitt" NAME="Sejvar 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sejvar JJ, Holman RC, Bresee JS, Kochanek KD, Schonberger LB</AU>
<TI>Amyotrophic lateral sclerosis mortality in the United States, 1979-2001</TI>
<SO>Neuroepidemiology</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>3</NO>
<PG>144-52</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:13:11 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:13:11 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="15990445"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Veldink-2007" MODIFIED="2011-03-01 15:13:50 +0000" MODIFIED_BY="Kate Jewitt" NAME="Veldink 2007" TYPE="JOURNAL_ARTICLE">
<AU>Veldink JH, Kalmijn S, Groeneveld G-J, Wunderink W, Koster A, de Vries JHM, et al</AU>
<TI>Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>2007</YR>
<VL>78</VL>
<PG>367-71</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:13:50 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:13:50 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="16648143"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yoshida-2006" MODIFIED="2011-03-28 10:48:20 +0100" MODIFIED_BY="Kate Jewitt" NAME="Yoshida 2006" TYPE="JOURNAL_ARTICLE">
<AU>Yoshida H, Yanai H, Namiki Y, Fukatsu-Sasaki K, Furutani N, Tada N</AU>
<TI>Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury</TI>
<SO>CNS Drug Reviews</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>1</NO>
<PG>9-20</PG>
<IDENTIFIERS MODIFIED="2011-03-01 15:14:13 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-03-01 15:14:13 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="16834755"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-05-10 22:23:50 +0100" MODIFIED_BY="Ruth Brassington">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-05-10 22:23:50 +0100" MODIFIED_BY="Ruth Brassington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-05-10 19:58:32 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Apostolski-1998">
<CHAR_METHODS MODIFIED="2011-03-01 12:28:59 +0000" MODIFIED_BY="Kate Jewitt">
<P>Double-blind, placebo controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-05-10 19:58:32 +0100" MODIFIED_BY="Ruth Brassington">
<P>Country: Yugoslavia<BR/>Single centre<BR/>Diagnosis: ALS, World Federation of Neurology<BR/>Participants: 35 (14 treated with antioxidant, 7 placebo, 7 nimodipine, 7 amino acids. 60% male)<BR/>Age: mean 54 years<BR/>Inclusion criteria not stated<BR/>Exclusion criteria - family history of neurological disease<BR/>Side effects - none</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-01 12:29:33 +0000" MODIFIED_BY="Kate Jewitt">
<P>1. Alsamin - selenium, vitamin E, b-carotene, L-arginine, L-leucine, L-isoleucine, L-valine, L-methionine, nimodipine<BR/>2. selenium, vitamin E, b-carotene<BR/>3. L-arginine, L-methionine, L-leucine, L-isoleucine, L-valine<BR/>4. nimodipine<BR/>5. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-01 12:29:39 +0000" MODIFIED_BY="Kate Jewitt">
<P>Primary: Erythrocyte enzyme activity of Copper zinc superoxide dismutase, glutathione peroxidase, catalase, glutathione reductase, and plasma activity of glutathione transferase<BR/>Secondary: Change in Norris score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-05-10 19:58:33 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Desnuelle-2001">
<CHAR_METHODS MODIFIED="2011-03-01 12:29:47 +0000" MODIFIED_BY="Kate Jewitt">
<P>Randomized, placebo controlled, double-blind study<BR/>Duration: 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-05-10 19:58:33 +0100" MODIFIED_BY="Ruth Brassington">
<P>Country: France<BR/>Multicentre: 28 sites<BR/>Diagnosis: probable or definite ALS by El Escorial criteria<BR/>Number of participants: 288 (144 treated, 144 placebo, 55% male)<BR/>Age: mean 64 years<BR/>Inclusion criteria: to have been treated with riluzole for at least 3 months without side effects<BR/>Exclusion criteria: dementia and/or major psychiatric disorders, or other serious disease or handicap, forced vital capacity less than 60%, monoclonal gammopathy, conduction blocks, abnormal liver function tests as defined, taking vitamin E or hepatotoxic drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-01 12:30:15 +0000" MODIFIED_BY="Kate Jewitt">
<P>1. a-tocopherol (500 mg capsules twice daily, Toco 500) plus riluzole 50 mg twice daily<BR/>2. placebo twice daily (identically-appearing capsules) plus riluzole 50 mg twice daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-01 12:30:26 +0000" MODIFIED_BY="Kate Jewitt">
<P>Primary: the change in functional status of each patient using the modified Norris limb scale<BR/>Secondary: included survival, bulbar function assessed with the Norris bulbar scale, manual muscle testing Fatigue, limb stiffness, cramps and fasciculations were assessed using visual analogue scales. Respiratory function, quality of life using the Sickness Impact Profile, the ALS Health State scale. Biological markers of oxidative stress - plasma thiobarbituric acid, erythrocyte superoxide dismutase, erythrocyte glutathione peroxidase - in a subgroup of 122 patients</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-01 12:31:27 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Ellis-1997">
<CHAR_METHODS MODIFIED="2011-03-01 12:30:52 +0000" MODIFIED_BY="Kate Jewitt">
<P>Randomized, placebo controlled, double-blind study<BR/>Duration: 6 months observation, followed by randomization and 6 months treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-01 12:31:08 +0000" MODIFIED_BY="Kate Jewitt">
<P>Country: USA<BR/>Single centre<BR/>Diagnosis: ALS<BR/>Number of participants: 10 (5 treated, 5 placebo, sex not stated)<BR/>Age: not stated<BR/>Inclusion criteria: not stated<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-01 12:31:22 +0000" MODIFIED_BY="Kate Jewitt">
<P>1. Coenzyme Q (240 mg)<BR/>2. Vitamin E (1600 IU)<BR/>3. Vitamin C (2000 mg)<BR/>4. Selenium (100 mg)<BR/>5. Beta-carotene (10 mg)<BR/>6. N-acetylcysteine (200 mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-01 12:31:25 +0000" MODIFIED_BY="Kate Jewitt">
<P>Primary: rate of change in Appel Rating Scale score.<BR/>Secondary: included safety and blood markers of oxidative damage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-01 12:31:27 +0000" MODIFIED_BY="Kate Jewitt">
<P>Presented in abstract form only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-05-10 19:58:34 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Graf-2005">
<CHAR_METHODS MODIFIED="2011-03-01 12:31:36 +0000" MODIFIED_BY="Kate Jewitt">
<P>Randomized, double-blind, placebo controlled study<BR/>Duration 18 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-05-10 19:58:34 +0100" MODIFIED_BY="Ruth Brassington">
<P>Country: Germany<BR/>Multicentre: 6 sites<BR/>Diagnosis: Probable or definite ALS - El Escorial criteria<BR/>Number of participants: 160 (83 treated, 77 placebo)<BR/>Age: mean 59 years treated, 57 years placebo<BR/>Inclusion criteria: Disease duration less than 5 years. Treated with riluzole<BR/>Exclusion criteria: Not stated<BR/>Side effects. No difference between treated and placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-01 12:31:57 +0000" MODIFIED_BY="Kate Jewitt">
<P>1. Vitamin E, a-tocopherol, 1 g five times daily<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-04 12:45:27 +0100" MODIFIED_BY="Kate Jewitt">
<P>Primary: Survival, calculated as time to death, tracheostomy, or permanent assisted ventilation<BR/>Secondary: Rate of deterioration of function assessed by modified Norris limb and bulbar scales, manual muscle testing (BMRC), spasticity scale, ventilatory function, Sickness Impact Profile (SIP ALS/19)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-01 12:32:12 +0000" MODIFIED_BY="Kate Jewitt">
<P>7 patients in placebo group were taking open vitamin E<BR/>23% of patients were taking vitamin E at onset of study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-04 12:45:27 +0100" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Jossan-1994">
<CHAR_METHODS MODIFIED="2011-04-04 12:45:27 +0100" MODIFIED_BY="Kate Jewitt">
<P>Randomized, cross-over, double-blind study<BR/>Duration: 12 weeks drug, 12 weeks washout, 12 weeks placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-01 12:32:36 +0000" MODIFIED_BY="Kate Jewitt">
<P>Country: Sweden<BR/>Single centre<BR/>Diagnosis: ALS - World Federation of Neurology (1990)<BR/>Number of participants: 10 (80% male)<BR/>Age: mean 50 years<BR/>Inclusion criteria: not stated<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-01 12:32:42 +0000" MODIFIED_BY="Kate Jewitt">
<P>1. Deprenyl (selegiline) 10 mg daily<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-01 12:32:46 +0000" MODIFIED_BY="Kate Jewitt">
<P>Primary: not stated<BR/>Other: Norris score, bulbar and spinal scores. MAO-B estimation in platelets</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-01 12:33:23 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Lange-1998">
<CHAR_METHODS MODIFIED="2011-03-01 12:32:56 +0000" MODIFIED_BY="Kate Jewitt">
<P>Randomized, placebo controlled, double-blind study<BR/>Duration: 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-01 12:33:12 +0000" MODIFIED_BY="Kate Jewitt">
<P>Country: USA<BR/>Multicentre: 2 sites<BR/>Diagnosis: criteria for classical ALS<BR/>Number of participants: 133 (67 treated, 66 placebo, 62% male)<BR/>Age: mean 57 years<BR/>Inclusion criteria: 25 to 65 years, symptom duration less than 3 years, mild to moderate disease with Appel ALS total score 30 to 80, no drug therapy for at least 3 months before enrolment<BR/>Exclusion criteria: multifocal motor neuropathy with conduction block, paraproteinemia, elevated GM1 antibodies, sensorimotor peripheral neuropathy, previous infection with poliovirus, lower motor neuron disease only, primary lateral sclerosis, previous allergy to selegiline, abnormal endocrinology, serious medical problems, poor family support</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-01 12:33:16 +0000" MODIFIED_BY="Kate Jewitt">
<P>1. selegiline 5 mg twice daily<BR/>2. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-01 12:33:20 +0000" MODIFIED_BY="Kate Jewitt">
<P>Primary: rate of change of Appel ALS (AALS) total score<BR/>Secondary: AALS component scores, survival analysis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-01 12:33:23 +0000" MODIFIED_BY="Kate Jewitt">
<P>Subjects with AALS score below 115 or forced vital capacity below 39% predicted were considered treatment failures and entered an open-label phase</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-01 12:34:00 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Louwerse-1995">
<CHAR_METHODS MODIFIED="2011-03-01 12:33:33 +0000" MODIFIED_BY="Kate Jewitt">
<P>Randomized, placebo controlled, double-blind study<BR/>Duration: 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-01 12:33:51 +0000" MODIFIED_BY="Kate Jewitt">
<P>Country: Netherlands<BR/>Single centre<BR/>Diagnosis: Probable or definite ALS by El Escorial criteria<BR/>Number of participants: 110 (54 treated, 56 placebo, 55% male)<BR/>Age: mean 58 years<BR/>Inclusion criteria: not stated<BR/>Exclusion criteria: younger than 20 years, older than 80 years, first or second degree family member with ALS, signs of dementia or parkinsonism, serious mental illness, life expectancy less than 6 months due to other disease, previously used drugs such as antioxidants, mucolytic drugs, glutamate antagonists, chelating agents</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-01 12:33:56 +0000" MODIFIED_BY="Kate Jewitt">
<P>1. Acetylcysteine 50 mg/kg sc infusion daily<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-01 12:34:00 +0000" MODIFIED_BY="Kate Jewitt">
<P>Primary: survival - death from all causes, long-term assisted ventilation, tracheostomy, positive-pressure breathing<BR/>Secondary: rates of disease progression as expressed by manual muscle strength testing, myometry, forced vital capacity, ability to perform activities of daily living, degree of independence, bulbar function</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-04 12:45:27 +0100" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Mitchell-1995">
<CHAR_METHODS MODIFIED="2011-04-04 12:45:27 +0100" MODIFIED_BY="Kate Jewitt">
<P>Cross-over, placebo controlled, double-blind study.<BR/>Duration: 4 week placebo, 16 weeks medication/placebo, 4 weeks placebo, 16 weeks medication/placebo, 4 weeks placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-01 12:34:22 +0000" MODIFIED_BY="Kate Jewitt">
<P>Country: England<BR/>Single centre<BR/>Diagnosis: MND diagnosed by two consultant neurologists<BR/>Number of participants: 56 (66% male)<BR/>Age: not stated<BR/>Inclusion criteria: not stated<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-01 12:34:25 +0000" MODIFIED_BY="Kate Jewitt">
<P>1. Selegiline 10 mg daily<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-01 12:34:31 +0000" MODIFIED_BY="Kate Jewitt">
<P>Primary: not stated<BR/>Other: hand held myometry, hand grip strength, Barthel Disability Index, Rankin Disability Scale, Bulbar Rating Scale, Quality of Life Scale. Whole blood and serum glutathione peroxidase, erythrocyte SOD, serum caeruloplasmin, leucocyte and plasma ascorbic acid, serum tocopherol</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-01 12:34:34 +0000" MODIFIED_BY="Kate Jewitt">
<P>This is published as a letter with no details of clinical results. Additional details are given in Mitchell 1994, and in unpublished information provided by Professor Mitchell</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-05-10 22:23:50 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-QALS-Study-Group-2009">
<CHAR_METHODS MODIFIED="2011-04-04 13:01:47 +0100" MODIFIED_BY="Kate Jewitt">
<P>An adaptive, two stage, bias-adjusted, randomized, placebo-controlled, double-blind, Phase II study of coenzyme Q10. Coenzyme Q10 1800 mg/day and 2700 mg/day. A total of 185 patients with ALS was studied</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-28 10:47:24 +0100" MODIFIED_BY="Kate Jewitt">
<P>The study was conducted at 19 centres in the USA. Diagnosis was of definite, probable, or laboratory supported probable ALS, sporadic or familial, by El Escorial guidelines</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-28 10:47:24 +0100" MODIFIED_BY="Kate Jewitt">
<P>The design was innovative, aiming to minimize sample size and length of follow up. In Stage 1, 35 patients were allocated to each of placebo, CoQ10 1800 mg/day and CoQ10 2700 mg/day, for 9 months. The dose of 2700 mg/day had higher efficacy, and was chosen Stage 2. In Stage 2, 40 patients were added to each of the placebo and CoQ10 2700 mg/day groups, and studied for a further 9 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-05-10 22:23:50 +0100" MODIFIED_BY="Ruth Brassington">
<P>The primary outcome was decline in the ALS Functional Rating Scale-revised (ALSFRSr) score from baseline to 9 months. Secondary outcome measures were decline in forced vital capacity, fatigue severity (9-item Fatigue Severity Scale), and quality of life (SF-36 with physical and mental components analyzed separately). Oxidative stress was assessed in plasma by 8-hydroxy-2 deoxyguanosine measurement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stevic-2001">
<CHAR_METHODS>
<P>Double-blind, placebo controlled study.<BR/>Duration 12 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Yugoslavia.<BR/>Centres: not stated (presumed single centre).<BR/>Diagnosis: ALS.<BR/>Number of participants: 28 (16 treated, 12 placebo; 75% male).<BR/>Age: mean 57 years.<BR/>Inclusion criteria: probable or definite ALS by El Escorial criteria, age 20-70 years, disease duration &lt;3 years, ambulatory.<BR/>Exclusion criteria: significant compromise of bulbar or respiratory function, conduction block, M protein, significant imaging abnormality, dementia, concurrent systemic disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Alsemet - L-methionine (2 g), vitamin E (400 IU), selenium (3 x 10-5g) three times daily.<BR/>2. Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary: survival and rate of disease progression as expressed by decline in limb-function, bulbar-function and muscle-testing scores.<BR/>Secondary: activity of antioxidative components (GSH-Px, GR, CAT), and level of vitamin E, in blood.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Published in abstract form as Stevic 1998</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-05-10 19:58:39 +0100" MODIFIED_BY="Ruth Brassington" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-04-04 13:01:50 +0100" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Ascherio-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-04-04 13:01:50 +0100" MODIFIED_BY="Kate Jewitt">
<P>A prospective study of prevention of disease in patients taking vitamin C and E. 957,740 patients were studied, with recruitment in 1982. ALS deaths were assessed from 1989 to 1998. Regular use of vitamin E was associated with a less than half the risk of dying from ALS than in non users. No significant association was found for use of vitamin C or multivitamins. This was not a randomized controlled trial of treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-04-04 13:01:50 +0100" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Chio-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-04-04 13:01:50 +0100" MODIFIED_BY="Kate Jewitt">
<P>An open, cross-over, sequentially randomized trial. Thirty-two patients were studied, and treated with reduced glutathione (GSH), 600 mg IM, daily, for 12 weeks, with 1 week washout. No significant difference in rate of progression of MRC score, bulbar score, Norris score, or forced vital capacity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-10 19:58:38 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Dorman-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-10 19:58:38 +0100" MODIFIED_BY="Ruth Brassington">
<P>An unblinded nonrandomized study of 12 patients treated with pancreatic extract (Viokase) 6.3 g and DL a-tocopherol 1500 units daily for variable periods of time. No improvement in muscle testing scores was observed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-04-04 13:01:52 +0100" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Janik-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-04-04 13:01:52 +0100" MODIFIED_BY="Kate Jewitt">
<P>An abstract of preliminary results of the study Kwiecinski 2001. The study is a randomized open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-04-04 13:01:53 +0100" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Mazzini-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-04-04 13:01:53 +0100" MODIFIED_BY="Kate Jewitt">
<P>An open randomized study. Fifty-three patients were given selegiline 10 mg daily for six months, and 58 patients were not. There was no statistically significant difference in mortality, mean MRC and Norris disability scores, and forced vital capacity</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-01 12:39:03 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Norris-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-01 12:39:03 +0000" MODIFIED_BY="Kate Jewitt">
<P>Brief descriptions of uncontrolled studies of vitamin E in ALS, with no benefit</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-10 19:58:39 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Quick-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-10 19:58:39 +0100" MODIFIED_BY="Ruth Brassington">
<P>Nonrandomized. No concealment. No controls. Ten patients were given vitamin E (900 to 2100 IU) and pancreatic supplement Viokase (5 to 7 g) daily. The seven patients followed for six months or more showed "physical changes were we interpret as favorable, reflecting remission of the usual relentless progression of ALS. One has shown marked improvement in muscle strength and function to levels 50% greater than the initial performance. The other three have improved less dramatically but all have achieved up to 25% improvement."</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-04-04 13:01:54 +0100" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Szczudlik-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-04-04 13:01:54 +0100" MODIFIED_BY="Kate Jewitt">
<P>An open randomized study. Nineteen patients were given pimozide 1 mg daily, and 25 selegiline and vitamin E, for 3 to 12 months. A significant decrease of an index of progression of the disease was reported in the pimozide treated patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-10 19:58:39 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Vyth-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-10 19:58:39 +0100" MODIFIED_BY="Ruth Brassington">
<P>Nonrandomized. No concealment. Historical controls. Patients received a variety of medications including N-acetylcysteine, vitamin C, vitamin E, N-acetylmethionine, dithiothreitol, dithioerythritol, and meso-2,3-dimercaptosuccinic acid (DMSA). The median survival in the treated group was 3.4 years, and in the untreated 2.8 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-04-04 13:01:55 +0100" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Wechsler-1940">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-04-04 13:01:55 +0100" MODIFIED_BY="Kate Jewitt">
<P>Non randomized. No concealment. No controls. Twenty patients were given a-tocopherol acetate 30 to 200 mg oral, or 50 mg IM, plus 2 teaspoonfuls of whole wheat germ oil, 2.5 g bile salts, whole vitamin B complex, and vitamin E containing foods. Duration of treatment 3 to 42 months. Fourteen patients were reported to be improved, and 2 stabilised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-04-04 13:01:55 +0100" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Zhang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-04-04 13:01:55 +0100" MODIFIED_BY="Kate Jewitt">
<P>An open randomized study. 50 patients with ALS were randomly divided to receive edaravone 30 mg/day intravenously. All patients received vitamin E 100 mg four times a day, and polysacharidum of Ganoderma lucidum Karst 2 ml four times a day intramuscularly (an extract of Reishi mushroom). The treatment was given for 14 days, repeated every three months. There was no indication of placebo injection. The trial lasted 27 months, with follow up for 18 months. The absolute changes of ALS-FRS score were stated to be significantly different between the two groups (P &lt; 0.05), but the changes of ALS-FRS score between the two groups were not significant (P = 0.08)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-05-10 19:58:37 +0100" MODIFIED_BY="Ruth Brassington">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-05-10 19:58:35 +0100" MODIFIED_BY="Ruth Brassington" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 22:25:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Apostolski-1998">
<DESCRIPTION>
<P>Comment: not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-01 12:30:30 +0000" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Desnuelle-2001">
<DESCRIPTION>
<P>"patients were randomly assigned to one of the two treatment groups according to a randomization schedule prepared by Labaratoire Rhone-Poulenc Rorer (now trading under the name Laboratoire Aventis"</P>
<P>Comment: probably adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-04 13:01:46 +0100" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Ellis-1997">
<DESCRIPTION>
<P>"randomized"</P>
<P>Comment: not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:27:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graf-2005">
<DESCRIPTION>
<P>Comment: not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:34:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jossan-1994">
<DESCRIPTION>
<P>Comment: not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:21:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lange-1998">
<DESCRIPTION>
<P>Comment: not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:39:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Louwerse-1995">
<DESCRIPTION>
<P>"randomization was balanced for prognostic factors according to the minimization method described by Pocock and Simon".</P>
<P>Comment: not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:49:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mitchell-1995">
<DESCRIPTION>
<P>Comment: not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 19:58:35 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-QALS-Study-Group-2009">
<DESCRIPTION>
<P>"Participants were randomized in permuted blocks, stratified by clinical site and riluzole use"</P>
<P>Comment: probably done but sequence generation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-04 13:01:49 +0100" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Stevic-2001">
<DESCRIPTION>
<P>"sixteen patients were randomized to Alsemet and 12 to placebo"</P>
<P>Comment: not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-05-10 19:58:37 +0100" MODIFIED_BY="Ruth Brassington" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 22:25:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Apostolski-1998">
<DESCRIPTION>
<P>Comment: not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:06:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Desnuelle-2001">
<DESCRIPTION>
<P>Comment: probably adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:57:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ellis-1997">
<DESCRIPTION>
<P>Comment: not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:27:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graf-2005">
<DESCRIPTION>
<P>Comment - not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:35:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jossan-1994">
<DESCRIPTION>
<P>Comment: not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:21:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lange-1998">
<DESCRIPTION>
<P>Comment: not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:43:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Louwerse-1995">
<DESCRIPTION>
<P>Comment: not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:49:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mitchell-1995">
<DESCRIPTION>
<P>Comment: not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 19:58:37 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-QALS-Study-Group-2009">
<DESCRIPTION>
<P>Comment: probably done but allocation concealment not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:14:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stevic-2001">
<DESCRIPTION>
<P>Comment: not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-04-04 12:45:27 +0100" MODIFIED_BY="Kate Jewitt" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-13 22:26:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Apostolski-1998">
<DESCRIPTION>
<P>"double blind"</P>
<P>Comment: not addressed further</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-04 12:45:27 +0100" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Desnuelle-2001">
<DESCRIPTION>
<P>"double blind, placebo controlled". "identically appearing capsules, bid, Rhone-Poulenc Rorer"</P>
<P>Comment: probably adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-13 21:58:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ellis-1997">
<DESCRIPTION>
<P>"double blind"</P>
<P>Comment: probably adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-13 21:28:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graf-2005">
<DESCRIPTION>
<P>"identical capsules"</P>
<P>Comment: probably adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-13 21:36:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jossan-1994">
<DESCRIPTION>
<P>"double blind"</P>
<P>Comment: not addressed further</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-04 12:45:27 +0100" MODIFIED_BY="Kate Jewitt" RESULT="YES" STUDY_ID="STD-Lange-1998">
<DESCRIPTION>
<P>"The research team at each site consisted of 2 investigators and a study coordinator unaware of randomization status and another investigator who reviewed laboratory data."</P>
<P>Comment: appears adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-13 21:44:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Louwerse-1995">
<DESCRIPTION>
<P>"the drug code was known only to the hospital pharmacists until the final analysis of the trial". "double blind"</P>
<P>Comment: probably adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-13 21:50:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mitchell-1995">
<DESCRIPTION>
<P>"double blind"</P>
<P>Comment: probably adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-13 20:54:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-QALS-Study-Group-2009">
<DESCRIPTION>
<P>"double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-13 21:15:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stevic-2001">
<DESCRIPTION>
<P>"double blind"</P>
<P>Comment: not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-05-10 19:58:37 +0100" MODIFIED_BY="Ruth Brassington" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-13 22:26:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Apostolski-1998">
<DESCRIPTION>
<P>Comment: not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-04 13:01:46 +0100" MODIFIED_BY="Kate Jewitt" RESULT="YES" STUDY_ID="STD-Desnuelle-2001">
<DESCRIPTION>
<P>"Intent to treat population which included all randomized patients who had received at least one treatment dose"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-13 21:59:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ellis-1997">
<DESCRIPTION>
<P>Comment: not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-13 21:29:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graf-2005">
<DESCRIPTION>
<P>Comment: not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-13 21:36:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jossan-1994">
<DESCRIPTION>
<P>Comment: not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-13 21:24:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lange-1998">
<DESCRIPTION>
<P>Comment: not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-13 21:45:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Louwerse-1995">
<DESCRIPTION>
<P>Comment:not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-13 21:50:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mitchell-1995">
<DESCRIPTION>
<P>Comment: not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-10 19:58:37 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-QALS-Study-Group-2009">
<DESCRIPTION>
<P>"Scoring for deceased patients". Imputation for missing data".</P>
<P>Comment: these are described in the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-13 21:18:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stevic-2001">
<DESCRIPTION>
<P>Comment: not addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-02-13 22:26:56 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 22:26:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Apostolski-1998">
<DESCRIPTION>
<P>Comment: insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:09:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Desnuelle-2001">
<DESCRIPTION>
<P>Appears adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:59:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ellis-1997">
<DESCRIPTION>
<P>Comment: insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:29:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Graf-2005">
<DESCRIPTION>
<P>Comment: probably adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:37:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jossan-1994">
<DESCRIPTION>
<P>Comment: appears adequate, but limited information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:24:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lange-1998">
<DESCRIPTION>
<P>Comment: appears adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:46:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Louwerse-1995">
<DESCRIPTION>
<P>Comment: appears adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:51:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mitchell-1995">
<DESCRIPTION>
<P>Comment: appears adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 20:57:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-QALS-Study-Group-2009">
<DESCRIPTION>
<P>Comment: sufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:18:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stevic-2001">
<DESCRIPTION>
<P>Appears adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-04-04 12:45:27 +0100" MODIFIED_BY="Kate Jewitt" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 22:27:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Apostolski-1998">
<DESCRIPTION>
<P>Comment: insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:10:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Desnuelle-2001">
<DESCRIPTION>
<P>Appears adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:59:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ellis-1997">
<DESCRIPTION>
<P>Comment: insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-04 12:45:27 +0100" MODIFIED_BY="Kate Jewitt" RESULT="NO" STUDY_ID="STD-Graf-2005">
<DESCRIPTION>
<P>Comment: 7 patients in placebo group were taking open vitamin E. 23% of patients were taking vitamin E at onset of study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:37:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jossan-1994">
<DESCRIPTION>
<P>Comment: appears adequate, but limited information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:24:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lange-1998">
<DESCRIPTION>
<P>Comment: appears adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:46:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Louwerse-1995">
<DESCRIPTION>
<P>Comment: appears adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:52:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mitchell-1995">
<DESCRIPTION>
<P>Comment: insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 20:58:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-QALS-Study-Group-2009">
<DESCRIPTION>
<P>Comment: the study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-13 21:18:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stevic-2001">
<DESCRIPTION>
<P>Appears adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2011-02-13 22:00:47 +0000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-05-10 20:01:17 +0100" MODIFIED_BY="Ruth Brassington">
<COMPARISON ID="CMP-001" MODIFIED="2011-05-10 20:01:17 +0100" MODIFIED_BY="Ruth Brassington" NO="1">
<NAME>All antioxidants versus placebo</NAME>
<DICH_OUTCOME CHI2="2.9455610685670037" CI_END="1.1939863645104436" CI_START="0.9733522456204398" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.078039567518941" ESTIMABLE="YES" EVENTS_1="222" EVENTS_2="198" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.07699936711857118" LOG_CI_START="-0.011729964823844577" LOG_EFFECT_SIZE="0.03263470114736329" METHOD="MH" NO="1" P_CHI2="0.4000951333233034" P_Q="1.0" P_Z="0.14937239285956572" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="287" WEIGHT="99.99999999999999" Z="1.441751842255978">
<NAME>Survival at 12 months (relative risk)</NAME>
<GROUP_LABEL_1>Antioxidant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antioxidant</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1488847058974145" CI_START="0.8864534331641409" EFFECT_SIZE="1.0091743119266054" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="109" LOG_CI_END="0.06027644809221578" LOG_CI_START="-0.05234407365701306" LOG_EFFECT_SIZE="0.003966187217601383" ORDER="1" O_E="0.0" SE="0.06615385195607061" STUDY_ID="STD-Desnuelle-2001" TOTAL_1="144" TOTAL_2="144" VAR="0.0043763321286257074" WEIGHT="54.123813139679314"/>
<DICH_DATA CI_END="1.3554914144567323" CI_START="0.9258416267876157" EFFECT_SIZE="1.1202546033189362" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="53" LOG_CI_END="0.1320967711486152" LOG_CI_START="-0.0334632967896029" LOG_EFFECT_SIZE="0.04931673717950613" ORDER="2" O_E="0.0" SE="0.09725080344246291" STUDY_ID="STD-Graf-2005" TOTAL_1="83" TOTAL_2="77" VAR="0.009457718770204557" WEIGHT="27.30397408273501"/>
<DICH_DATA CI_END="1.5387074115341552" CI_START="0.8225247961456943" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="30" LOG_CI_END="0.1871560456685862" LOG_CI_START="-0.08485100077382365" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="3" O_E="0.0" SE="0.1597782855368668" STUDY_ID="STD-Louwerse-1995" TOTAL_1="56" TOTAL_2="54" VAR="0.025529100529100533" WEIGHT="15.167307101694954"/>
<DICH_DATA CI_END="2.999095002266106" CI_START="0.8804739423075137" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.4769902231141292" LOG_CI_START="-0.05528349248434281" LOG_EFFECT_SIZE="0.21085336531489315" ORDER="4" O_E="0.0" SE="0.31266021533992816" STUDY_ID="STD-Stevic-2001" TOTAL_1="16" TOTAL_2="12" VAR="0.09775641025641026" WEIGHT="3.4049056758907037"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.270913746773108" CI_END="0.12586537596169106" CI_START="-0.018433545232878414" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RD" EFFECT_SIZE="0.05371591536440632" ESTIMABLE="YES" EVENTS_1="222" EVENTS_2="198" I2="8.282509651634061" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.9000937226073182" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.269897019125874" METHOD="MH" NO="2" P_CHI2="0.35171153005565214" P_Q="1.0" P_Z="0.14450714525769662" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="287" WEIGHT="100.0" Z="1.4592106252669654">
<NAME>Survival at 12 months (risk difference)</NAME>
<GROUP_LABEL_1>Antioxidant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antioxidant</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.10553188392025396" CI_START="-0.09164299503136512" EFFECT_SIZE="0.00694444444444442" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="109" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="5" O_E="0.0" SE="0.050300638304302876" STUDY_ID="STD-Desnuelle-2001" TOTAL_1="144" TOTAL_2="144" VAR="0.0025301542138203015" WEIGHT="49.21670185289475"/>
<DICH_DATA CI_END="0.22015036875569596" CI_START="-0.05460507068027734" EFFECT_SIZE="0.08277264903770931" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="53" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6" O_E="0.0" SE="0.07009196128174015" STUDY_ID="STD-Graf-2005" TOTAL_1="83" TOTAL_2="77" VAR="0.00491288303632096" WEIGHT="27.30416159217451"/>
<DICH_DATA CI_END="0.25286337363616807" CI_START="-0.1139744847472792" EFFECT_SIZE="0.06944444444444442" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="30" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7" O_E="0.0" SE="0.09358280592832763" STUDY_ID="STD-Louwerse-1995" TOTAL_1="56" TOTAL_2="54" VAR="0.008757741565419034" WEIGHT="18.791831616559815"/>
<DICH_DATA CI_END="0.6539773524499675" CI_START="-0.02897735244996752" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8" O_E="0.0" SE="0.17422634045497637" STUDY_ID="STD-Stevic-2001" TOTAL_1="16" TOTAL_2="12" VAR="0.030354817708333332" WEIGHT="4.687304938370928"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.006993032966295" CI_END="1.1739814419771375" CI_START="0.9548463762588955" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0587596165641484" ESTIMABLE="YES" EVENTS_1="209" EVENTS_2="192" I2="0.0" I2_Q="100.00000000000001" ID="CMP-001.03" LOG_CI_END="0.06966123174070438" LOG_CI_START="-0.020066495756396085" LOG_EFFECT_SIZE="0.02479736799215416" METHOD="MH" NO="3" P_CHI2="0.6044136841148491" P_Q="0.0" P_Z="0.2786661576355448" Q="1.733213060404799E-32" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="283" TOTAL_2="275" WEIGHT="100.0" Z="1.0833206085059728">
<NAME>Survival at 12 months (sensitivity analysis)</NAME>
<GROUP_LABEL_1>Antioxidant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antioxidant</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1488847058974145" CI_START="0.8864534331641409" EFFECT_SIZE="1.0091743119266054" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="109" LOG_CI_END="0.06027644809221578" LOG_CI_START="-0.05234407365701306" LOG_EFFECT_SIZE="0.003966187217601383" ORDER="9" O_E="0.0" SE="0.06615385195607061" STUDY_ID="STD-Desnuelle-2001" TOTAL_1="144" TOTAL_2="144" VAR="0.0043763321286257074" WEIGHT="56.031637546804994"/>
<DICH_DATA CI_END="1.3554914144567323" CI_START="0.9258416267876157" EFFECT_SIZE="1.1202546033189362" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="53" LOG_CI_END="0.1320967711486152" LOG_CI_START="-0.0334632967896029" LOG_EFFECT_SIZE="0.04931673717950613" ORDER="10" O_E="0.0" SE="0.09725080344246291" STUDY_ID="STD-Graf-2005" TOTAL_1="83" TOTAL_2="77" VAR="0.009457718770204557" WEIGHT="28.266418987201277"/>
<DICH_DATA CI_END="1.5387074115341552" CI_START="0.8225247961456943" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="30" LOG_CI_END="0.1871560456685862" LOG_CI_START="-0.08485100077382365" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="11" O_E="0.0" SE="0.1597782855368668" STUDY_ID="STD-Louwerse-1995" TOTAL_1="56" TOTAL_2="54" VAR="0.025529100529100533" WEIGHT="15.701943465993727"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.053014176128732" CI_START="0.9533196803165543" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0019277108433735" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="75" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.022434217883531483" LOG_CI_START="-0.020761441316816176" LOG_EFFECT_SIZE="8.363882833576765E-4" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9394980805240554" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="77" WEIGHT="100.0" Z="0.07590072441626877">
<NAME>Survival at 3 months (relative risk)</NAME>
<GROUP_LABEL_1>Antioxidant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antioxidant</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0530141761287322" CI_START="0.9533196803165543" EFFECT_SIZE="1.0019277108433735" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="75" LOG_CI_END="0.022434217883531577" LOG_CI_START="-0.020761441316816176" LOG_EFFECT_SIZE="8.363882833576765E-4" ORDER="12" O_E="0.0" SE="0.025373344036245762" STUDY_ID="STD-Graf-2005" TOTAL_1="83" TOTAL_2="77" VAR="6.438065875816884E-4" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2076329799460819" CI_START="0.9908202589288213" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0938680093508362" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="67" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.08193496491169062" LOG_CI_START="-0.004005122139644743" LOG_EFFECT_SIZE="0.03896492138602295" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.07552201565640322" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="77" WEIGHT="100.0" Z="1.777281015119774">
<NAME>Survival at 6 months (relative risk)</NAME>
<GROUP_LABEL_1>Antioxidant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antioxidant</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2076329799460819" CI_START="0.9908202589288214" EFFECT_SIZE="1.0938680093508362" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="67" LOG_CI_END="0.08193496491169062" LOG_CI_START="-0.004005122139644694" LOG_EFFECT_SIZE="0.03896492138602295" ORDER="13" O_E="0.0" SE="0.05048163254424621" STUDY_ID="STD-Graf-2005" TOTAL_1="83" TOTAL_2="77" VAR="0.0025483952243322977" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1899537599559626" CI_START="0.9153774823531985" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0436746987951808" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="64" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.07553008560585893" LOG_CI_START="-0.03839977511828035" LOG_EFFECT_SIZE="0.018565155243789298" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.5229777441221145" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="77" WEIGHT="100.0" Z="0.6387620491053987">
<NAME>Survival at 9 months (relative risk)</NAME>
<GROUP_LABEL_1>Antioxidant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antioxidant</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1899537599559626" CI_START="0.9153774823531985" EFFECT_SIZE="1.0436746987951808" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="64" LOG_CI_END="0.07553008560585893" LOG_CI_START="-0.03839977511828035" LOG_EFFECT_SIZE="0.018565155243789298" ORDER="14" O_E="0.0" SE="0.06692296415126546" STUDY_ID="STD-Graf-2005" TOTAL_1="83" TOTAL_2="77" VAR="0.004478683130791562" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2865103634302892" CI_START="0.8356440702082324" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0368532955350815" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.10941328900144523" LOG_CI_START="-0.07797866425951919" LOG_EFFECT_SIZE="0.015717312370963018" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.7423219575971391" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="77" WEIGHT="100.0" Z="0.32878003185071036">
<NAME>Survival at 15 months (relative risk)</NAME>
<GROUP_LABEL_1>Antioxidant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antioxidant</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2865103634302892" CI_START="0.8356440702082324" EFFECT_SIZE="1.0368532955350815" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="51" LOG_CI_END="0.10941328900144523" LOG_CI_START="-0.07797866425951919" LOG_EFFECT_SIZE="0.015717312370963018" ORDER="15" O_E="0.0" SE="0.11007496095061939" STUDY_ID="STD-Graf-2005" TOTAL_1="83" TOTAL_2="77" VAR="0.012116497028280382" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3430977192905624" CI_START="0.8188581537781119" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0487166055526453" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.1281076116298259" LOG_CI_START="-0.0867913221305598" LOG_EFFECT_SIZE="0.020658144749633043" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.7063066056495712" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="77" WEIGHT="99.99999999999999" Z="0.37682103850586657">
<NAME>Survival at 18 months (relative risk)</NAME>
<GROUP_LABEL_1>Antioxidant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antioxidant</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3430977192905624" CI_START="0.8188581537781119" EFFECT_SIZE="1.0487166055526453" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="46" LOG_CI_END="0.1281076116298259" LOG_CI_START="-0.0867913221305598" LOG_EFFECT_SIZE="0.020658144749633043" ORDER="16" O_E="0.0" SE="0.1262326974577289" STUDY_ID="STD-Graf-2005" TOTAL_1="83" TOTAL_2="77" VAR="0.015934693907454514" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.16977193383339798" CI_START="-0.006417216261812936" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.08167735878579252" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="67" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.7701341043673907" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.0878983145462937" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.0691878505999505" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="77" WEIGHT="100.0" Z="1.8171911435636225">
<NAME>Survival at 6 months (risk difference)</NAME>
<GROUP_LABEL_1>Antioxidant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours antioxidant</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.16977193383339798" CI_START="-0.006417216261812936" EFFECT_SIZE="0.08167735878579252" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="67" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17" O_E="0.0" SE="0.04494703767134713" STUDY_ID="STD-Graf-2005" TOTAL_1="83" TOTAL_2="77" VAR="0.0020202361954294984" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-05-10 19:58:38 +0100" MODIFIED_BY="Ruth Brassington">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-05-10 19:58:38 +0100" MODIFIED_BY="Ruth Brassington" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVEAAAJGCAIAAABtLyGrAAAa2UlEQVR42u3dv44kt9nF4QacOJhg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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-05-11 09:48:53 +0100" MODIFIED_BY="Ruth Brassington">
<APPENDIX ID="APP-01" MODIFIED="2011-03-28 12:56:07 +0100" MODIFIED_BY="Kate Jewitt" NO="1">
<TITLE MODIFIED="2010-05-11 14:07:02 +0100" MODIFIED_BY="Angela Gunn">MEDLINE OvidSP search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-03-28 12:56:07 +0100" MODIFIED_BY="Kate Jewitt">
<P>1 randomized controlled trial.pt.<BR/>2 controlled clinical trial.pt.<BR/>3 randomized.ab.<BR/>4 placebo.ab.<BR/>5 drug therapy.fs.<BR/>6 randomly.ab.<BR/>7 trial.ab.<BR/>8 groups.ab.<BR/>9 or/1-8<BR/>10 exp animals/ not humans.sh.<BR/>11 9 not 10<BR/>12 exp Motor Neuron Disease/<BR/>13 (moto$1 neuron$1 disease$1 or moto?neuron$1 disease).mp.<BR/>14 amyotrophic lateral sclerosis.mp.<BR/>15 (Lou Gehrig$1 adj5 (syndrome$ or disease$)).tw.<BR/>16 or/12-15<BR/>17 Ascorbic Acid/<BR/>18 vitamin c.tw.<BR/>19 ascorbic acid.mp.<BR/>20 Vitamin E/<BR/>21 vitamin E.tw.<BR/>22 alpha-Tocopherol/<BR/>23 alpha-tocopherol.mp.<BR/>24 selegiline.mp.<BR/>25 Selegiline/<BR/>26 deprenyl.mp.<BR/>27 Acetylcysteine/<BR/>28 n-acetyl cysteine.mp.<BR/>29 n-acetylcysteine.mp.<BR/>30 n-acetyl-l-cysteine.mp.<BR/>31 Acetylcysteine.mp.<BR/>32 Superoxide Dismutase/<BR/>33 Superoxide Dismutase.mp.<BR/>34 SOD.mp.<BR/>35 DEHYDROEPIANDROSTERONE/<BR/>36 DEHYDROEPIANDROSTERONE.mp.<BR/>37 ANTIOXIDANTS/<BR/>38 antioxidant.mp.<BR/>39 anti oxidant.mp.<BR/>40 or/17-39<BR/>41 aeol-10150.mp.<BR/>42 (catalytic adj1 metalloporphyrin).mp.<BR/>43 (coQ10$ or coenzyme q10$ or ubiquinone).mp.<BR/>44 or/17-43<BR/>45 11 and 16 and 44</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-03-28 12:56:11 +0100" MODIFIED_BY="Kate Jewitt" NO="2">
<TITLE MODIFIED="2010-05-11 14:07:14 +0100" MODIFIED_BY="Angela Gunn">EMBASE OvidSP search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-03-28 12:56:11 +0100" MODIFIED_BY="Kate Jewitt">
<P>1 crossover-procedure/<BR/>2 double-blind procedure/<BR/>3 randomized controlled trial/<BR/>4 single-blind procedure/<BR/>5 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or (doubl$ adj blind$) or (singl$ adj blind$) or assign$ or allocat$ or volunteer$).tw.<BR/>6 or/1-5<BR/>7 human/<BR/>8 6 and 7<BR/>9 nonhuman/ or human/<BR/>10 6 not 9<BR/>11 8 or 10<BR/>12 exp Motor Neuron Disease/<BR/>13 (moto$1 neuron$1 disease$ or moto?neuron$1 disease$).mp.<BR/>14 amyotrophic lateral sclerosis.mp.<BR/>15 (lou gehrig$1 adj5 (disease$ or syndrome$)).mp.<BR/>16 or/12-15<BR/>17 Ascorbic Acid/<BR/>18 vitamin c.tw.<BR/>19 ascorbic acid.mp.<BR/>20 vitamin E.tw.<BR/>21 alpha-Tocopherol/<BR/>22 alpha-tocopherol.mp.<BR/>23 selegiline.mp.<BR/>24 Selegiline/<BR/>25 deprenyl.mp.<BR/>26 Acetylcysteine/<BR/>27 n-acetyl cysteine.mp.<BR/>28 n-acetylcysteine.mp.<BR/>29 n-acetyl-l-cysteine.mp.<BR/>30 Acetylcysteine.mp.<BR/>31 Superoxide Dismutase/<BR/>32 Superoxide Dismutase.mp.<BR/>33 SOD.mp.<BR/>34 prasterone/<BR/>35 prasterone.mp.<BR/>36 DEHYDROEPIANDROSTERONE.mp.<BR/>37 ANTIOXIDANT/<BR/>38 antioxidant.mp.<BR/>39 anti oxidant.mp.<BR/>40 (aeol-10150 or aeol10150).mp.<BR/>41 (catalytic adj1 metalloporphyrin).mp.<BR/>42 (coQ10$ or coenzyme Q10$ or ubiquinone).mp.<BR/>43 or/17-42<BR/>44 11 and 16 and 43<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-05-11 09:48:53 +0100" MODIFIED_BY="Ruth Brassington" NO="3">
<TITLE MODIFIED="2011-05-10 20:01:36 +0100" MODIFIED_BY="Ruth Brassington">Cochrane Central Register of Controlled Trials (CENTRAL) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-05-11 09:48:53 +0100" MODIFIED_BY="Ruth Brassington">
<P>#1MeSH descriptor Motor Neuron Disease explode all trees<BR/>#2"motor neuron disease" OR "motor neurone disease" OR "motoneuron disease" OR "motorneuron disease" OR "amyotrophic lateral sclerosis"<BR/>#3(Gehrig* NEAR syndrome*)<BR/>#4(Gehrig* NEAR disease*)<BR/>#5(#1 OR #2 OR #3 OR #4)<BR/>#6(ascorbic acid) or (vitamin c) or (vitamin e) or (alpha tocopherol)<BR/>#7selegiline or deprenyl or acetylcysteine or (acetyl NEAR/3 cysteine)<BR/>#8(superoxide dismutase) or sod or dehydroepiandrosterone or antioxidants or antioxidant or (anti oxidant)<BR/>#9aeol-10150<BR/>#10catalytic NEAR metalloporphyrin<BR/>#11COQ10 * or "coenzyme q10*" or ubiquinone<BR/>#12(#6 OR #7 OR #8 OR #9 OR #10 OR #11)<BR/>#13(#5 AND #12)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>